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Abbreviations 
°C Degrees Celsius 
A Ampere 
AKT Protein kinase B 
AMCase Acidic mammalian chitinase 
APC Allophycocyanin 
APS Ammonium persulfate 
BSA Bovine serum albumin 
CCL Chemokine (C-C motif) ligand 
CCR Chemokine (C-C motif) receptor 
CD Cluster of differentiation 
cDNA Complementary deoxyribonucleic acid 
CLP Chitinase-like proteins 
cm centimeter 
CO2 Carbon dioxide 
CR Complement receptors 
CSF Colony stimulating factors 
CXCL Chemokine (C-X-C motif) ligand 
DAPI 4’, 6-Diamidino-2-phenylindole 
ddH2O double distilled H2O 
DMEM Dulbecco´s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTP Deoxynucleotides 
E. coli Escherichia coli 
ECF Eosinophil chemotactic cytokine 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF  Epidermal growth factor 
ERK Extracellular signal-regulated kinase 
F Forward 
FACS Fluorescence-Activated Cell Sorting 
FCS Fetal Calf Serum 
FGF Fibroblast growth factor 
GlcNAc N-Acetylglucosamine 
g gram(s) 
h hour(s) 
HCl Hydrochloric acid 
HLA Human leukocyte antigen (Histocompatibility antigen) 
HMVECs Human microvascular endothelial cells 
HRP Horseradish peroxide 
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IFN Interferon 
Ig Immunoglobulin 
IHC Immunohistochemistry 
IL Interleukin 
kb kilobase 
kDa Kilodalton 
ko knockout 
LB Lysogeny broth 
LPS Lipopolysaccharides 
M Molar 
mA milliampere 
MAPK Mitogen-activated protein kinase 
MCP Monocyte chemoattractant protein 
mg milligrams 
MHC Major histocompatibility complex 
mi micro 
MIF Macrophage migration inhibitory factor 
min minute(s) 
MIP Macrophage Inflammatory Protein 
ml milliliter 
mM millimolar 
MMP Metalloproteinase 
mRNA messenger ribonucleic acid 
MW Molecular weight 
NA Not Applicable 
NF-κB Nuclear factor 'Kappa-light-chain-enhancer' of activated B cells 
ng nanogram(s) 
NK Natural killer 
NOS Nitric oxide synthases 
P/S Penicillin/Streptomycin 
PAGE Polyacrylamide gel electrophoresis 
PBS  Phosphate-buffered saline 
PD Programmed cell death 
PDGF Platelet-derived growth factor 
PFA Paraformaldehyde 
Pr Probe 
R Reverse 
RCF  Relative Centrifugal Force  
RNA Ribonucleic acid 
rpm revolutions per min 
RT-PCR Real-time polymerase chain reaction 
S100A9 S100 calcium-binding protein A9 
SDF Stromal cell-derived factor 
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SDS Sodium dodecyl sulfate 
sec second(s) 
SFM Serum-free medium 
sh small hairpin 
si short interfering 
SI-CLP Stabilin-1-interacting chitinase-like protein 
st stock concentration 
STAT Signal transducers and activators of transcription 
TAE Tris-Acetate-EDTA 
TAM Tumor-associated macrophages 
TEMED Tetramethylethylenediamine 
TGF Transforming growth factor 
TGS Tris-Glycine-SDS 
Th Helper T 
TNF Tumor necrosis factor 
Tris (hydroxymethyl) aminomethane 
uPA Urokinase-type plasminogen activator 
VEGF Vascular endothelial growth factor 
VSMC Vascular smooth muscle cells 
wd working dilution 
wt wide type 
μg microgram(s) 
μl microliter 
μM micromolar 
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1 Introduction 
1.1  Chitinase-like protein family 
1.1.1 Structure and properties of chitinase-like proteins 
Chitinases and chitinase-like proteins, characterized by the presence of an 18-times α/β 
barrel structure, are widely found in bacteria, fungi, insects, protozoan parasites, plants and 
mammals, and serve as a component of the host defense mechanism against chitin-containing 
organisms1,2. Some plants increase the production of chitinases to inhibit fungal growth by 
degrading part of their cell walls containing chitin3. Chitin, composed of N-acetylglucosamine 
repeats of β-(1-4)-poly-N-acetyl D-glucosamine, is mainly found in lower life forms, 
including mushrooms, as well as the cell walls of fungi and bacteria, the exoskeleton of 
insects and crustaceans, and the microfilaria sheath of parasitic nematodes1,4.  
In mammals, true chitinases are represented by acidic mammalian chitinase (AMCase) 
and chitotriosidase that possess a chitin binding domain and enzymatic activity, and are able 
to hydrolyze chitin into oligosaccharides of varying sizes5. Similar to the true chitinases, 
chitinase-like proteins also contain a typical Glyco_18 domain, but they do not possess 
enzymatic activity doe to the substitution of glutamic acid at the end of the DxxDxDxE 
conserved motif with either leucine, isoleucine or tryptophan (Figure 1A)6,7. In total, six 
Glyco_18 domain-containing proteins have been found in human, including AMCase, 
chitotriosidase, oviductin, stabilin-1-interacting chitinase-like protein (SI-CLP), chitinase-3-
like protein 1 (YKL-40) and chitinase-3-like protein 2 (YKL-39)7. 
Even though mammalian chitinase-like proteins do not hydrolyze chitin, they can bind 
chitin due to their lectin properties as summarized in the Table 1. The lectin properties of 
chitinase-like proteins are important for their interaction with specific carbohydrate polymer 
components of extracellular matrix (ECM) or cell surface glycoproteins7,8. For example, 
YKL-40 induces the interaction of αvβ3 integrin and syndecan-1 on human microvascular 
endothelial cells (HMVECs) through its heparin binding activity, which results in enhanced 
tube formation in vitro and increased angiogenesis in vivo9. SI-CLP demonstrates the 
strongest binding affinity to N-acetylglucosamine tetramer (GlcNAc)4, which is a component 
of chitin10. Moreover, SI-CLP protein purified from E. coli bind with lipopolysaccharides 
(LPS) and neutralizes the toxic effect of endotoxin11. Human YKL-39 protein purified from 
Pichia pastoris yeast demonstrates the strongest interaction with (GlcNAc)5 and (GlcNAc)6 
via hydrogen bonds and hydrophobic interactions12. YM1 specifically binds saccharides with 
Introduction 
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a free amino group, such as glucosamine, galactosamine or glucosamine polymers, but fails to 
bind chitin fragments4.  
 
 
Figure 1. Structure of mammalian chitinases and chitinase-like proteins. Domain organization of 
mammalian Glyco_18 domain-containing proteins (Kzhyshkowska, J. et al., 2016), Copyright 
Portland Press Limited
7
. 
 
 
 
 
Chitin binding domain
YKL-40
22
22  30                104 105                 243
YKL-39
22 365
YM1
23 418
Chitotriosidase
AMCase
22 360
Oviductin
Glyco_18 domain
81 384
SI-CLP
393
360 364 385
357 383
398
363 466
136-140
1 257
136-140
321 368
390 678
O-glycosylated region
Catalytic site Chitin binding groove
A
309 381
B
FDGIDIDWEYP         Glyco_18 prototype catalytic domain
1-186-FDGFVVEVMNQ-393     SI-CLP
1-131-FDGLDVSWIYP-385     YKL-39
1-131-FDGLDLAWLYP-383     YKL-40
1-131-FDGLNLDWQYP-398     YM-1
1-131-FDGLDLDWEYP-466     Chitotriosidase
1-131-FDGLDFDWEYP-368     AMCase
1-132-FDGLDLFFLYP-678     Oviductin
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Table 1. Lectin properties of chitinase-like proteins 
Chitinase-
like protein 
Source of the protein Carbohydrate binding Functions mediated by 
interaction with 
carbohydrates 
Reference 
YKL-40 Bovine nasal cartilage 
and chondrocytes 
Collagen type I Facilitates type I collagen 
fibril formation 
(Bigg et 
al.,2006)
13
 
Human YKL-40 
transfected CHO cells 
Chitooligosaccharides, 
(GlcNac)5 and 
(GlcNac)4 
Involved in defense against 
chitin-containing organisms 
(Fusetti et 
al., 2003)
8
 
Human peripheral 
blood monocyte- 
derived macrophages 
Chitin Interfere with hyphal growth 
of fungi 
 
(Renkema 
et al., 
1998)
14
 
Nodular smooth 
muscle cell  
Heparin Enhancing ECM-cell 
interaction 
(Shackelton 
et al., 
1995)
15
 
YKL-39 Pichia pastoris yeast 
cells 
Chitooligosaccharides, 
(GlcNac)5 and 
(GlcNac)6 
unknown (Rank et 
al., 2015; 
Schimpl et 
al., 2012) 
12,16
 
SI-CLP E. coli Galactosamine, 
Glucosamine, ribose, 
(GlcNac)4, mannose, 
Ghitooligosacharide 
LPS sensing  (Meng et 
al., 2010)
10
 
YM1 Mouse peritoneal 
exudate fluid 
Galactosamine,  
Glucosamine polymers 
and heparin 
Preventing inflammation via 
competing for binding sites 
on local ECM occupied by 
infiltrating leukocytes 
(Chang et 
al., 2001)
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 11 
1.1.2 Identification and cell specific expression of chitinase-like proteins  
In mammals, chitinase-like proteins are expressed in various cell types, and elevated 
expression of chitinase-like proteins is associated with several pathological processes (Table 
2). YKL-40, a secreted glycoprotein of 40 kDa molecular weight, was initially isolated from 
conditioned medium of cultured human chondrocytes using heparin-agarose affinity 
chromatography
17
. In vitro, the expression of YKL-40 in human monocyte-derived 
macrophages is elevated under IFN-γ stimulation6. YKL-40 expression in bronchial 
epithelium cells is increased under strong mechanical stress
18
. In serum and synovial fluid of 
rheumatoid arthritis patients, increased YKL-40 expression is due to its production by 
chondrocytes, macrophages and neutrophils
19,20
. Endogenous expression of YKL-40 in 
glioblastoma cell lines (MG-63 and U-87 MG) is vital for tumor proliferation, migration and 
angiogenesis
21,22
.  
Similarly to YKL-40, YKL-39 was also purified out of human articular cartilage 
chondrocytes using heparin-agarose affinity chromatography
23
. Expression of YKL-39 was 
found in human macrophages, chondrocytes and synoviocytes
23-25
. In comparison with normal 
chondrocytes, YKL-39 expression is up-regulated in osteoarthritic chondrocytes
25
. In human 
monocytes-derived macrophages expression of YKL-39 was significantly increased under 
stimulation with  IL-4 and TGF-β26.  
YM1 gene is present in rodents, but absent in human
27
. YM1 protein was found in mouse 
macrophages, neutrophils and bone marrow derived mast cells
4,28-31
. In vitro, YM1 expression 
in macrophages was induced by IL-4 or IL-13 via STAT-6 dependent signaling pathway, and 
IFN-γ antagonized the stimulating effect of IL-429,32. However, YM1 protein was also found 
in wound-healing macrophages where IL-4 was absent
31
. It was hypothesized that YM1 
originates from neutrophils that were phagocytosed by macrophages during late stages of 
infection or inflammation
28
.  
SI-CLP, a stabilin-1 interacting chitinase-like protein, was identified as a ligand for the 
multifunctional receptor stabilin-1 using yeast two-hybrid screening
6
. Endogenous SI-CLP 
expression was found in various cell lines including those of monocytic, T-cell, B-cell and 
epithelial origin. Expression of SI-CLP is strongly up-regulated in primary human monocyte-
derived macrophages stimulated by IL-4 and dexamethasone and suppressed by IFN-γ6. IL-12 
slightly enhances the expression of SI-CLP gene in mouse bone marrow derived-macrophages, 
whereas IL-4 fails to increase SI-CLP expression
11
.  
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Table 1. Expression profile of chitinase-like proteins 
Chitinase-
like protein 
Cell type  Biological activity, 
mechanism 
Associated disorder 
or pathological 
process 
Reference 
YKL-40 Human chondrocytes  Promotes chondrocyte 
proliferation  
Rheumatoid 
arthritis 
and osteoarthritis 
(Petersson et al., 
2006)
19
 
Human bronchial 
epithelial cells  
Induces airway hyper-
responsiveness 
Asthma (Park et al., 2010)33 
Human colonic 
epithelial cells 
Enhances the migration 
and proliferation of 
colonic epithelial cells 
Neoplastic 
progression of the 
colon 
(Chen et al., 2011)34 
Human peripheral 
blood monocyte-
derived macrophages 
Unknown Inflammation (Kzhyshkowska et 
al., 2006)6 
Human neutrophils Suggested function in 
degradation of ECM 
Rheumatoid 
arthritis 
 
(Volck et al., 1998)20 
Human synovial 
cells 
Not available Rheumatoid 
arthritis 
(Hakala et al., 
1993)17 
Vascular smooth 
muscle cells 
(VSMC) 
Promotes migration of 
vascular endothelial cell  
Promotes tumor 
angiogenesis 
(Malinda et al., 
1999)35 
U-87 MG cells Promotes proliferation 
and migration of tumor 
cells  
Promotes tumor 
progression 
(Ku et al., 2011)21 
MG-63 cells Promotes angiogenesis Promotes tumor 
progression 
(Faibish et al., 
2011)22 
YKL-39 Human osteoarthritic 
chondrocytes 
Unknown Osteoarthritis (Knorr et al., 2003)24 
Human monocyte-
derived macrophages  
Unknown Unknown (Kzhyshkowska et 
al., 2008)26 
SI-CLP Cell lines: Raji, 
MonoMac-6, THP-1, 
U937, Jurkat, A549, 
HEK293 
Unknown Unknown (Kzhyshkowska et 
al., 2006)6 
Human monocyte-
derived macrophages 
Unknown Unknown (Kzhyshkowska et 
al., 2006)6 
Peripheral blood 
mononuclear cells 
derived from 
rheumatoid arthritis 
patients 
Aggregates 
inflammation 
Rheumatoid 
arthritis 
(Xiao et al., 2014)11 
YM1 Mouse macrophages Biomarker of 
alternatively activation 
macrophages  
Infection and 
allergic peritonitis 
(Welch et al., 2012)36 
Mouse neutrophils Suggested function in 
the digestion of 
glycosaminoglycans 
Mouse chronic 
granulomatous 
disease 
(Harbord et al., 
2002)28 
Mouse bone 
marrow-derived 
mast cells 
Unknown Unknown (Lee et al., 2005)30 
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1.2 Biological activities of chitinase-like proteins 
1.2.1 Cytokine-like activity 
Chitinase-like proteins exert direct or indirect chemotactic activity towards various cells 
as summarized in the Table 3. For the first time the chemotactic activity of chitinase-like 
proteins was demonstrated for murine YM1 protein (originally named ECF-L) that induced 
the recruitment of eosinophils, T lymphocytes and bone marrow cells
37
. The chemotactic 
activity of YM1 protein was concentration dependent and was abrogated by a specific anti-
YM1 antibody
37
. The presence of a CXC motif on the N-terminus of the YM1 protein was 
suggested to mediate its chemotaxic activity.  
Table 2. Chemotactic activity of chitinase-like proteins 
Chitinase-
like protein 
Chemotaxis for 
cell types 
Concentration In vitro model Mechanism Reference 
YM1 Eosinophils,  
T lymphocytes, 
bone marrow 
cells 
1x10
-8 
M Microchemotaxis 
Transwell (3 µm 
for eosinophils 
and bone marrow 
cells, 8 µm for T 
lymphocytes) 
CXC motif in N-
terminus 
(Owhashi 
et al., 
2000)
37
 
YKL-40 VSMC  1 ng/ml Microchemotaxis 
Transwell with 
polycarbonate 
membrane of 12 
µm pore size 
Binding with integrin 
on the VSMC 
(Nishikawa 
and Millis, 
2003)
38
 
YKL-40 THP-1 80 ng/ml Transwell with  
8 µm pore size 
membrane pre-
coated with 
fibronectin 
YKL-40 induced   
IL-8 and MCP-1 
secretion in SW480 
cells 
(Kawada et 
al., 2012)
39
 
YKL-40 Bronchial 
smooth muscle 
cells 
100 ng/ml Chemicon 
Transwell with 8 
µm pore size 
polycarbonate 
membrane 
YKL-40 stimulated 
IL-8 secretion in 
BEAS-2B and 
HBECs 
(Tang et 
al., 2013)
40
 
 
Unlike ECF-L, YKL-40 does not contain typical CXC or CC sequences on its N-
terminus
37
. The chemotactic activity of YKL-40 can be direct and indirect. Purified YKL-40 
protein used at the concentration 80 ng/ml directly induces chemotaxis of human monocyte-
like THP-1 cells
39
. Indirect effect was shown for YKL-40-transfected SW480 cells (human 
colon carcinoma cell line) that secreted elevated levels of IL-8 and MCP-1, that in turn 
exerted a chemotactic effect on THP-1 cells
39
. Similarly, bronchial epithelial cells stimulated 
with YKL-40 secreted elevated levels of IL-8 that mediated enhanced chemotaxis of human 
Introduction 
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bronchial smooth muscle cells
40
. Moreover, the adhesion and migration of VSMC was 
enhanced under stimulation of YKL-40
38
. 
1.2.2 Growth factor-like activity 
Growth factors are secreted mediators that induce cellular growth and proliferation 
through their binding to specific growth factor receptors on the cell surface. Growth factors 
can activate ERK1/2-MAPK and AKT signaling pathways that participate in various cellular 
activities including cell survival, cell cycle progression and cell migration. Growth factor 
activities were also reported for the chitinase-like proteins. Purified YKL-40 protein directly 
promotes the proliferation of HEK-293 and U-373 MG cells via the activation of the ERK1/2-
MAPK signaling pathway
41
. However, the effect of YKL-40 on the stimulation of 
proliferation was not limited to the tumor cells. YKL-40-stimulated proliferation was 
demonstrated for human synovial cells and skin fibroblasts, and was mediated by the direct 
activation of ERK1/2-MAPK and AKT signaling pathways
42
. YKL-40 can also promote cell 
proliferation indirectly. For instance, YKL-40 increases the secretion of IL-8 in human 
bronchial epithelial cells via the activation of the MAPK pathway, and IL-8 induces the 
proliferation of human bronchial smooth muscle cells
43
. In addition, purified YKL-39 protein 
can also activate the ERK1/2-MAPK signaling pathway in HEK-293 and U-373 MG cells, but 
it leads to the inhibition of proliferation of HEK-293 and U-373 MG cells
41
. The stimulation 
with YKL-40 and YKL-39 results in opposite effect in the proliferation of HEK-293 and U-
373 MG cells, however the mechanism of such opposite effects remains to be unknown. SI-
CLP protein was reported to activate the ERK signaling pathway in PMA treated THP-1 cells, 
but it was unknown whether the activation of ERK signaling pathway affects cell 
proliferation
11
. 
1.3 Role of chitinase-like proteins in tumor progression 
Among all chitinases and chitinase-like proteins, the function of YKL-40 in cancer 
progression is the best investigated. Increased expression of YKL-40 was found in the 
circulation of various solid tumors including glioblastoma, esophageal squamous cell 
carcinoma, breast, bladder, colon, head and neck, liver, lung, pancreas, prostate, stomach and 
endometrial cancers, and high YKL-40 levels in the serum of tumor patients are positively 
associated with a poor outcome or short disease-free survival
39,44-54
. As illustrated by Figure 2, 
YKL-40 participates in the tumor progression by affecting the tumor initiation, tumor growth 
and metastasis
22,55
. Preliminary data produced in our laboratory suggested that SI-CLP can 
Introduction 
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have an inhibitory effect on the tumor growth of TS/A breast adenocarcinoma in a mouse 
model (Nan Wang, PhD thesis 2014), however the mechanism of SI-CLP suppression of 
tumor growth remains to be identified. The role of YKL-39 in tumour progression also  
remains to be invesigated. 
   
Figure 2. YKL-40 supports tumor progression. YKL-40 involves tumor progression via affecting 
tumor initiation, tumor growth, tumor angiogenesis and metastasis (Kzhyshkowska, J. et al., 2016), 
Copyright Portland Press Limited
7
. 
 
1.3.1 Effects of chitinase-like proteins on the survival of tumor cells 
Endogenous YKL-40 was shown to support the survival of tumor cells
21,39
. The colony 
forming ability of U-87 MG (human primary glioblastoma cell line) was shown to be 
suppressed when YKL-40 gene expression was silenced, while the colony forming ability of 
U-373 MG cells (human primary glioblastoma cell line) was increased when YKL-40 was 
over-expressed in vitro
21
. YKL-40 protein exerts an anti-apoptotic effect in U-87 MG cells 
through activating the AKT signaling pathway
55
. In addition, YKL-40 is also able to attenuate 
ionizing irradiation induced tumor death through enhancing angiogenesis and proliferation of 
tumor cells
56
. YKL-40 antagonizes S100A9-regulated apoptosis through competitive binding 
with RAGE on mouse intestinal epithelial cells
57
. Overall, YKL-40 enhances the survival of 
tumor cells by promoting proliferation and inhibiting apoptosis of tumor cells (Figure 2). 
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1.3.2 Effects of chitinase-like proteins on tumor angiogenesis 
Besides direct proliferation of tumor cells, neovascularization is vital for tumor growth. 
The positive correlation between YKL-40 expression and blood vessel density was found in 
the abundantly vascularized tumors such as human breast cancer and glioblastoma by 
immunohistochemical analysis
9,56
. Recombinant YKL-40 protein was shown to increase the 
migration and tube formation of HMVECs in vitro
9,39
. By comparison to empty vector 
transfected MDA-MB-231 and HCT-116 cells, the conditioned medium of YKL-40 
transfected MDA-MB-231 and HCT-116 cells increased the migration and tube formation of 
HMVECs
9
. U-87 MG cells expressing endogenous YKL-40 protein enhance the tube 
formation of HMVECs through increasing VEGF production
55
, while tumor angiogenesis is 
suppressed when the YKL-40 gene in U-87 MG cells was silenced in vivo
9
. Transient 
suppression of VEGF protein in U-87 MG cells significantly enhanced YKL-40 expression, 
which promoted tumor angiogenesis and was associated with poor prognosis in 
glioblastoma
55,58
. However, pro-angiogenic effects of YKL-40 on HMVECs are not affected 
by VEGF since anti-VEGF neutralizing antibody failed to abrogate enhanced tube formation 
and migration of HMVECs induced by YKL-40
9
. The effects of SI-CLP and YKL-39 on 
tumor angiogenesis was not analyzed up to date. 
1.3.3 Effects of chitinase-like proteins on tumor metastasis 
Evidence accumulate that YKL-40 can support metastatic process. Elevated serum YKL-
40 levels were found to positively correlate with tumor metastasis in breast cancer and 
glioblastoma
44,45,59
. The adhesion ability of U-87 MG cells to ECM substrates is suppressed 
after the YKL-40 gene in U-87 MG cells is silenced
21
. Knockdown of YKL-40 gene leads to 
decreased invasion and MMP-2 expression in U-87 MG cells
21
, which are important for 
glioblastoma metastasis
60
. On another side, the adhesion and invasion ability of tumor cells is 
enhanced when YKL-40 gene in U-373 MG cells is overexpressed
21
. The ability of YKL-40 
to promote tumor metastasis was also demonstrated in melanoma animal models with lung 
metastasis. Increased lung metastasis was observed in YKL-40 transgenic mice injected by 
B16 cells from tail-vein, and pulmonary metastasis was decreased in YKL-40 ko mice
61,62
. In 
mammary tumor-bearing mice, increased YKL-40 expression in the metastasized lung 
induces the secretion of CCL2, CXCL2 and MMP9 by alveolar macrophages and lung 
interstitial macrophages
63
, and CCL2 recruited macrophages to the tumor microenvironment 
facilitating tumor metastasis into lungs
64
. 
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1.4 Macrophages 
1.4.1 Overview 
Macrophages are differentiated phagocytic cells of the mononuclear phagocyte system
65
. 
Macrophages are widely distributed in various organs and tissues, including the bone, central 
nervous system, gastrointestinal tract, liver, lymphoid organs, lungs, serous cavities, 
synovium and skin, and are key innate immune cells that control tissue homeostasis and 
inflammation
66
. Macrophages are regulate multiple physiological and pathological processes 
due to their ability to secrete various cytokines and chemokines, phagocytose pathogens and 
cellular debris, and activate non-specific and specific immunity
67
. Monocytes in peripheral 
blood circulation enter extra vascular tissues under specific signals, and differentiate into 
specific tissue macrophages to maintain tissue homeostasis (Table 4). 
Table 3. Terminology of tissue macrophages 
Tissue Name of macrophages 
Bone Osteoclasts 
Central nervous system Microglia 
Connective tissue Histiocytes 
Chorion villi of the placenta  Hofbauer cells 
Kidney Mesangial cells 
Liver  Kupffer cells  
Lung Alveolar macrophages  
Peritoneal cavity Peritoneal macrophages  
Skin and mucosa Langerhans cells 
Spleen White-pulp macrophages, red-pulp 
macrophages, marginal-zone macrophages 
Tumor Tumor-associated macrophages 
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1.4.2 Selected biological activities of macrophages 
1.4.2.1 Endocytosis and phagocytosis 
Endocytosis is one of the key biological processes applied by macrophages to acquire 
nutrients from the extracellular microenvironment and initiate non-specific innate immunity. 
Macrophages utilize different internalsation pathways depending on their targets, including 
clathrin-mediated endocytosis, caveolae-mediated endocytosis, macropinocytosis and 
phagocytosis. Engulfed vacuoles are directed to early endosomes, late endosomes and 
lysosomes for digestion. Macrophages are characterized by pronounced phagocytosis of 
apoptotic cells and cellular debris
68
, foreign microorganisms (bacteria, viruses, fungi and 
protozoa) and soluble antigens
69
. The process of phagocytosis includes several stages 
including sensing of pathogens, formation of phagosomes and intracellular digestion of 
pathogens. Pathogens are recognized via interacting with multiple surface receptors of 
macrophages, such as Fc receptors, complement receptors (CR1, CR3 and CR4), mannose 
receptors (CD205 and CD206) and scavenger receptors (CD36, MARCO and stabilin-1). 
Macrophages extend pseudopodia to capture and ingest pathogens followed by receptor-
mediated internalization and reorganization of the actin based cytoskeleton
69,70
. Ingested 
pathogens fuse with lysosomes to form macrophage phagosomes, where pathogens are 
degraded by multiple hydrolytic enzymes. Digested pathogens can be expelled to extracellular 
space or presented in the form of foreign peptides to immune cells to initiate adaptive 
immunity.  
Recently, endocytic function of TAM was demonstrated to regulate tumor growth in a 
mouse model of TS/A breast adenocarcinoma where tumor growth was impaired in stabilin-1 
knockout mice
68
. The tumor supportive role of multifunctional scavenging receptor stabilin-1 
was linked to the efficient endocytosis of the soluble component of extracellular matrix 
SPARC, that was shown to have an inhibitory effect of progression of breast cancer, while 
impaired SPARC clearance by stabilin-1 ko TAM correlated with the decrease of the tumor 
growth
68
.  
1.4.2.2 Secretion 
Macrophages participate in a broad range of physiological and pathological processes via 
secreting multiple substances, including immunity-associated cytokines, chemotaxis 
associated chemokines and cytokine inhibitors, complement components, coagulation factors 
and extracellular matrix components, enzymes, reactive oxygen and Glyco_18 domain 
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containing proteins
71
. Functionally, the cytokines secreted by macrophages could be divided 
into three groups: (a) cytokines that promote inflammatory response, e.g., IL-1β, TNF-α, IL-8, 
IL-12; (b) cytokines that suppress inflammation response, e.g., IL-10, TGF-β; (c) cytokines 
that regulate cell activation of natural killer and T cells, e.g., IL-1ra, IL-12, IL-18. Chitinase-
like proteins secreted by activated macrophages, including SI-CLP, YKL-39, YKL-40, YM1 
and chitotriosidase, play an important role in innate immunity, tumor progression and chronic 
inflammation
6,26,72
. Interestingly, transport of SI-CLP in the secretory pathway in alternatively 
activated macrophage is mediated by stabilin-1, frequently expressed on TAM in different 
types of tumors
6,73
. 
1.4.2.3 Antigen presentation and T cell activation 
Macrophages along with B cells and dendritic cells belong to professional antigen-
presenting cells which present antigens in the context of MHC class I and MHC class II 
molecules. Endogenous antigens are presented by macrophages in the context of MHC class I 
molecules, which are specifically targeted by CD8+ cytotoxic T cells. Extracellular antigens 
are internalized and re-presented by macrophages in association with MHC II molecule, 
which along with co-stimulatory signals activate immature CD4+ T cells or B cells
74
. 
1.4.3 Macrophage activation 
Macrophages are activated by a range of signals including various cytokines, immune 
complexes, glucocorticoids, LPS and interferon in the microenvironment. The activation 
states of macrophages are determined by intracellular signaling cascades, transcription factors, 
cytokines, chemokines, scavenger receptors and metabolic pathways (Figure 3). IFN-γ and 
IL-4 induce clear-cut antagonistic effects on macrophage polarization, which are designated 
as type I and type II activation respectively
75
. Mouse macrophages activated by IL-4 are 
characterized by increased expression of STAT6, Arg1 and chemokines such as CCL17, 
CCL22 and CCL24, while human macrophages stimulated by IL-4 are characterized by 
increased expression of IRF4, SOCS1, GATA3 and chemokines CCL4, CCL13, CCL17 and 
CCL18
75
. Specific membrane receptors (CD206 and stabilin-1) were found in IL-4 activated 
human macrophages, which are widely found in Th2 responses, type II inflammation and 
allergy reactions
76
. IFN-γ or LPS induces the up-regulation of transcription factors STAT1 
and NF-κB mediating the production of iNOS and the secretion of pro-inflammatory 
cytokines (TNF-α, IL-1β and IL-6)77. Macrophages under stimulation of LPS or IFN-γ are 
characterized by reduced phagocytic activity, enhanced Type I inflammatory response and 
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enhanced killing of intracellular pathogens
78
. Macrophages differentiated from mouse bone 
marrow precursors or human peripheral blood monocytes using CSF-1 or GM-CSF are widely 
used in vitro. Macrophages are innate immune cells with extreme phenotypic plasticity and 
can be polarized and re-polarized by multiple factors
79,80
. Recently, it has been found that 
each stimuli potentially induces a unique transcriptional program in macrophages which may 
reveal a certain degree of similarity with M1 (IFN-γ) and M2 (IL-4) macrophages81.  
      
Figure 3. Macrophage activation under different stimulations. (A) Widely used macrophage 
preparations in vitro and ex vivo. (B) The status of macrophage activation were indicated by 
transcription factors, cytokines, chemokines, scavenger receptors, matrix, amino acid metabolism and 
so on. (C) Genetics was used to aid in macrophage-activation studies. (Murray, P. J. et al., 2014), 
Copyright Elsevier
75
. 
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1.4.4 Role of tumor-associated macrophages in tumor progression. 
Most of solid tumor tissues are highly infiltrated by macrophages, and the amounts of 
tumor-associated macrophages (TAM) are positively associated with poor prognosis in most 
of published research
82
. TAM participate in all stages of tumor progression from tumor 
initiation to remote metastasis (Figure 4).  
 
Figure 4. The role of TAM in tumor progression. Major effects of TAM on tumor progression 
include: tumor growth, tumor migration and metastasis, tumor angiogenesis and tumor immune 
suppression. TAM expresses an array of cytokines, chemokines, enzymes and cell surface receptors to 
affect tumor progression. 
 
1.4.4.1 TAM and angiogenesis 
Extensive studies in mouse model of breast demonstrated that TAM are crucial cells for 
the angiogenic switch required for efficient primary tumor growth
83,84
. Macrophages are 
recruited into tumor tissue by chemokines such as CSF-1, MCP-1 and SDF-1
85
. CSF-1 ko 
mice are characterized by reduced macrophage infiltration in tumor tissue, which was 
associated with attenuated angiogenesis and tumor growth
83
. Recruited macrophages increase 
the secretion of VEGF-A, thymidine phosphorylase, Semaphorin-4D, MMPs and YKL-40 to 
promote angiogenesis
86
. In human lung cancer, YKL-40 mRNA was detected in TAM of the 
peritumoral stroma
87
. The positive correlation between TAM density and tumor vessel 
abundance was demonstrated by the extensive analysis of animal study and clinical material
88-
93
. VEGF-A is the most common cytokine secreted by TAM to promote tumor angiogenesis, 
and hypoxia-inducible factors are the most important regulators of VEGF-A production in 
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TAM
86
. However, targeting of -VEGF-A was not always successful in suppressing 
neovascularization, which can be partially explained by compensatory up-regulation of YKL-
40
58
. The application of anti-VEGF and anti-YKL-40 blocking antibodies was demonstrated 
to be more efficient in restricting growth of glioblastoma in the animal model and in reducing 
neo-angiogenesis in tumor tissue in comparison with single anti-VEGF or anti-YKL-40 
therapy
55
. Thymidine phosphorylases are abundantly found in many human solid tumor 
tissues, and its expression is positively associated with tumor angiogenesis and metastasis
94
. 
Thymidine phosphorylases derived from human monocyte cells (U937 and THP-1) enhance 
the migration of human umbilical vein endothelial cells in vitro and tumor angiogenesis in 
vivo through the intracellular metabolism of thymidine and subsequent extracellular release of 
2-deoxyribose
95
. In Semaphorin-4D ko mice, tumor growth and metastasis were impaired, 
accompanied by reduced tumor neo-angiogenesis
96
. MMP9 produced by TAM can enhance 
neovascularization in vivo via cleaving VEGF-A from its ECM-bound form
97
. Targeting 
MMP9 expressing macrophages is effective in impairing cervical carcinogenesis through 
inducing the apoptosis of neoplastic epithelial and endothelial cell
98
. 
1.4.4.2 TAM and tumor growth 
The supporting role of TAM in tumor growth was demonstrated in number of animal 
models. For example, the reduction of TAM in an animal tumor model bases on the 
subcutaneous injection of human A673 rhabdomyosarcoma demonstrates inhibition of tumor 
growth and progression
99
. Depleting TAM by injecting the bacterial pathogen inducing 
specific apoptosis of TAM suppressed tumor growth in animal breast cancer model 
100
. The 
infiltration of monocytes into the tumor microenvironment is mediated by CCL2 and CCL5, 
and targeting of CCL2 by siRNA or application of CCR5 antagonist was efficient in the 
inhibiting of tumor growth due to the reduction of the amount of TAM
101,102
. The tumor 
promoting effect of TAM is related to the increased secretion of soluble mediators, e.g., IL-1, 
IL-6, TNF-α, TGF-β, EGF (epidermal growth factor), FGF (fibroblast growth factor) and 
PDGF (platelet-derived growth factor)
97
.  Tumor cells express abundant receptors for growth 
factors and cytokines, including EGFR, FGFR and PDGFR, and that respond to TAM-
mediators by enhanced proliferation. In vitro, IL-1β released by macrophages induces the 
proliferation of colon cancer cells through the activation of Wnt signaling
103
. IL-6 can induce 
the proliferation of glioma stem cells via STAT3 activation, and silencing IL-6 receptor in 
glioma stem cells with shRNA increases the apoptosis of glioblastoma stem cells leading to 
the suppression of glioblastoma growth
104
. High IL-6 serum levels in human ductal breast 
Introduction 
 23 
carcinoma predict poor prognosis, and the application of anti-IL-6 monoclonal antibody 
inhibits the mammosphere formation of primary human breast cancer tissue and MCF7 tumor 
cells in Notch-3 dependent mechanism
105
. TNF-α released by TAM binds with TNFR1 and 
TNFR2 expressed by tumor cells, which improves the survival of tumor cells via elevating the 
expression of anti-apoptotic molecules
106
.  
1.4.4.3 TAM and tumor metastasis 
Tumor metastasis was shown to be significantly impaired when TAM in the tumor 
microenvironment were depleted or reduced
99,101
. Intra-vital and multi-photon imaging clearly 
demonstrated the coordination of TAM and tumor cells in case of inducing metastasis through 
the formation of a EGF/CSF-1 paracrine signaling loop
107,108
. Inhibition of EGF or CSF-1 in 
mammary tumor bearing mice reduces the amount of metastatic tumor cells
109
. TAM 
modulate the extracellular matrix to promote the migration and metastasis of tumor cells 
through increasing the production of MMPs, uPA, Cathepsin B and other factors
110
. MMP2 
and MMP9 are the most common proteases secreted by TAM, and the role of MMPs in 
promoting tumor metastasis has been widely revealed
111
. Tumor invasion and metastasis was 
inhibited when Cathepsin B from TAM was depleted in an autonomous breast tumor model
112
. 
Moreover, TAM can enhance tumor metastasis via other soluble cytokines or miRNA
113-116
. 
CCL18 released by TAM enhances the metastasis of breast cancer by interacting with its 
receptor expressed on breast cancer cells, and blocking the specific receptor of CCL18 
reverses the pro-metastasis effect of CCL18
114
. CXCL12 was secreted by TAM in a breast 
tumor model, and the binding of CXCL12 with CXCR7 enhanced the migration of tumor 
cells through up-regulation of vascular cell adhesion molecule 1 and MMPs
115
. Heparin 
binding EGF-like growth factor and Oncostatin M derived from TAM enhance the migration 
of tumor cells, and high heparin binding EGF-like growth factor levels in breast carcinoma 
patients positively correlate with TAM infiltration and tumor metastasis
116
.  
1.4.4.4 TAM and immune suppression 
TAM express various effector factors to suppress anti-tumor immune responses in the 
tumor microenvironment (Figure 5). The interaction between TAM and other immune cells is 
pivotal for tumor progression. TAM induce apoptosis of cytotoxic T cells by up-regulating the 
expression of FASL
117
. Some tumor cells up-regulate HLA molecules, e.g., HLA-C, HLA-G 
and HLA-E to inhibit the activity of NK cells and some subsets of activated T cells
84
. HLA 
negative tumor cells can induce the expression of HLA molecules on TAM, which inhibit the 
Introduction 
 24 
migration of NK cells to the lymph nodes via HLA-E-CD94 binding
118
. HLA-G expressed by 
TAM can interact with ILT2, the co-stimulatory receptor of T cells, to suppress the function 
of T cells
84
. PD-1 expression on T cells, NKT cells and B cells is a safety mechanism to 
down-regulate exaggerated immune reactions
119
. However, TAM strategically suppress the 
function of activated T cells, NKT cells and B cells in the tumor microenvironment by 
elevating PD-L1 and PD-L2 production
120
. Increased expression of arginase-I is a typical 
property of alternatively activated macrophages, and TAM impair T cell function by 
decreasing the expression of the CD3 ζ-chain121. IL-10 and TGF-β secreted by TAM enhance 
the regulatory functions of CD4+ T cells by up-regulating FoxP3 expression, known as Treg 
cells
122
. TAM recruit natural regulatory T cells by increasing the secretion of CCL5, CCL20 
and CCL22, which inhibit the non-specific and specific tumor killing function of NKT and T 
cells
84
.  
    
Figure 5. TAM regulate anti-tumor immune responses. TAM express various effector molecules, 
including cytokines, chemokines, enzymes and cells surface receptors to suppress the anti-tumor 
immune responses mediate by innate and adaptive immune cells (Noy, R. and Pollard, J.W. 2014), 
Copyright Elsevier
84
. 
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1.4.5 Immunotherapy of targeting tumor-associated macrophages 
Depleting TAM and interfering TAM derived pro-tumor cytokines are the most 
investigated strategies for targeting TAM. It is known that the recruitment of monocytes from 
the blood vessels to tumor tissue strongly depends on cytokine signals such as CCL2, CCL3, 
CCL4, CCL7, CCL8 and MIF
97
. Blocking CCL2-CCR2 interaction is efficient in reducing the 
infiltration of monocytes which suppressed tumor metastasis
64
. Even though majority of 
publications demonstrated that high TAM density predicts a poor prognosis for cancer 
patients, evidence accumulate that TAM density can also correlate with a good prognosis
97
. 
For example, the amount of CD68+ macrophages in the gaps of tumor ductal structures in 
human breast cancer was negatively associated with lymph node metastasis
123
. Roles of TAM 
in tumor progression are versatile, and in human tumor tissue TAM are represented by 
heterogeneous subpopulations; suggesting that, targeting tumor-supportive TAM 
subpopulations or their secreted factors as a promising therapeutic approach. Qian and Pollard 
proposed six phenotypes of TAM in mouse and human tumor tissue based on their function, 
including activated macrophages (IL-12
+
, MHC II
hi
, iNOS
+
, TNF-α+, CD80/86+), 
immunosuppressive macrophages (Arginase
+
, MARCO
+
, IL-10
+
, CCL22
+
), angiogenic 
macrophages (VEGFR1
+
, VEGF
+
, CXCR4
+
, Tie2
+
), metastasis-associated macrophages 
(VEGFR1
+
, CCR2
+
, CXCR4
-
, Tie2
-
), invasive macrophage (Wnt signaling, CTS B&S
+
, EGF
+
) 
and perivascular macrophages
110
. It was anticipated that reprogramming pro-tumor 
macrophages to anti-tumor macrophages can improve the anti-tumor response. However, such 
reprogramming in vivo is complicated due to the plasticity of the macrophage phenotype. An 
alternative approach is to silence the function of pro-tumor TAM specifically in the tumor 
microenvironment. 
Another approach for targeting TAM is the neutralization of the tumor-promoting 
soluble factors produced by TAM. TAM produce various cytokines to exert pro-tumor 
function, and blocking of these cytokines was found to be a promising strategy in some tumor 
models
93,96
. Tumor cell derived CSF-1 is important for monocyte chemotaxis, and TAM 
programmed by tumor cells facilitate their proliferation by secreting EGF
109
. Interrupting the 
CSF-1-EGF positive cycle has proved to be effective in inhibiting tumor growth and 
metastasis
124
. Targeting of CSF-1/CSF-1R signaling pathway was demonstrated to delay 
tumor initiation and to attenuate tumor growth in various mouse tumor models
110,125
. 
Similarly, inhibiting EGF secretion from TAM reduces tumor metastasis in mammary tumor 
bearing mice
107
.  
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In summary targeting of TAM by blocking of activity of TAM-released factors or 
depletion of TAM subpopulations is a very promising direction in anti-tumor therapy 
development. Chitinase-like proteins are known to be released by various subpopulations of 
macrophages, and our preliminary observations demonstrated that SI-CLP, in contrast to 
known activities of YKL-40, is able to suppress tumor growth in animal model for breast 
cancer (Nan Wang, PhD thesis 2014). However, the effect of SI-CLP on TAM and other 
components of tumor microenvironment remained to be investigated.  
1.5 Aims and objectives of the thesis 
The major aims of the thesis project were to identify the functional role and possible 
mechanism of SI-CLP in breast cancer development using mouse model for breast 
adenocarcinoma.  
Specific objectives included: 
1) To investigate the effect of SI-CLP on tumor growth of mouse model for breast 
adenocarcinoma; 
2) To investigate the effect of SI-CLP on proliferation and migration of tumor cells in vitro; 
3) To analyze the effect of SI-CLP on tumor angiogenesis in vivo; 
4) To analyze the effect of purified SI-CLP on the migration of human monocytes and 
mouse bone marrow derived macrophages in vitro; 
5) To investigate the effect of SI-CLP on recruitment and phenotype of TAM; 
6) To investigate the effect of SI-CLP on recruitment of other immune cells in tumor 
microenvironment in vivo. 
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2 Materials and Methods 
2.1 Chemicals, reagents and kits 
2.1.1 Chemicals and reagents 
Product Company 
0.22 µm filter Carl Roth 
3MM blotting papers GE Healthcare 
Acetic acid Merck 
Acetone Sigma-Aldrich 
Acrylamide / bis acrylamilde solution 30% Bio-Rad 
AEC+high sensitivity substrate chromogen Dako  
Agarose  Bioron 
Amersham Hyperfilm ECL GE Healthcare 
Ammonium persulfate (APS) Merck 
Bovine serum albumin Sigma-Aldrich 
CD11b MicroBeads, human and mouse Miltenyi Biotec 
CD14 MicroBeads, human Miltenyi Biotec 
Cell strainer Corning 
Collagenase IV Santa Cruz Biotechnology 
Dako Pen Dako  
DAPI Roche Diagnostics 
DMEM medium + GlutaMAX Thermo Fisher Scientific 
DMSO Sigma-Aldrich 
DNA ladder Thermo Fisher Scientific 
DNA Loading Dye (6x) Thermo Fisher Scientific 
DNase Thermo Fisher Scientific 
dNTP Thermo Fisher Scientific 
DPBS (sterile 1x) Thermo Fisher Scientific 
EDTA (0.5 M) Thermo Fisher Scientific 
Ethanol Merck 
Faramount Mounting Medium, Aqueous Dako  
Fetal calf serum  Biochrom  
Fluorescent Mounting Medium Dako  
Glycerol Sigma-Aldrich 
Isoflurane CP Pharmaceuticals 
Isopropanol Merck 
Laemmli sample buffer Bio-Rad 
LB broth with agar Sigma-Aldrich 
Macrophage-SFM medium Thermo Fisher Scientific 
Methanol Merck 
Mouse Genome 430 2.0 Array Affymetrix 
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Nitrocellulose blotting membrane GE Healthcare 
Non-Fat Dry Milk Bio-Rad 
O.C.T compound VWR 
PageRuler Plus prestained Protein ladder Thermo Fisher Scientific 
Paraformaldehyde (PFA) Sigma-Aldrich 
Penicillin / Streptomycin Biochrom 
Percoll Biochrom 
Peroxidase-Blocking Solution Dako 
Ponceau S solution Sigma-Aldrich 
Protein G Sepharose 4 Fast Flow GE healthcare  
Recombinant human MCP-1 (CCL2) Peprotech 
Recombinant human SI-CLP protein Cusabio 
Recombinant murine MCP-1 (CCL2) Peprotech 
Recombinant murine M-CSF Peprotech 
Recombinant murine MIP-3β (CCL19) Peprotech 
Recombinant murine SI-CLP protein  Cusabio 
Red blood cell lysis buffer Sigma-Aldrich 
Reduced serum medium+ GlutaMAX  Thermo Fisher Scientific 
RPMI medium +GlutaMAX Thermo Fisher Scientific 
Saponin VWR 
Sodium azide Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) 10% Bio-Rad 
TaqMan Probe MWG Biotech 
TEMED Sigma-Aldrich 
Tris/Glycine/SDS electrophoresis buffer (10x) Bio-Rad 
Triton X-100 Sigma-Aldrich 
Trypan blue solution Sigma-Aldrich 
Trypsin-EDTA solution (sterile 1x) Sigma-Aldrich 
Tween 20 Biochrom 
β-mercaptoethanol Sigma-Aldrich 
2.1.2 Kits 
Product Company 
Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit Thermo Fisher Scientific 
E.Z.N.A Total RNA Kit I Omega Biotech Corp 
Pan T Cell Isolation Kit II, mouse Miltenyi Biotec 
RevertAid H Minus First Strand cDNA Synthesis Kit Thermo Fisher Scientific 
RNeasy Mini Kit QIAGEN 
SensiFAST Probe No-ROX Kit Bioline 
Streptavidin/Biotin Blocking Kit Vector Laboratories 
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2.2 Equipment  
Product Company 
Agarose electrophoresis unit   VWR 
Balance Kern 
Blot chambers VWR 
Cell counter + Analyser System OMNI Life Science 
Cell culture hood Thermo Fisher Scientific 
Cell culture incubator Heraeus instruments 
Centrifuge 5804 R Eppendorf 
Centrifuge Universal 320 Hettich 
Confocal laser scanning microscope SP8 Leica Microsystems 
Cryostat microtome Leica Biosystems 
Digital caliper Fixpoint 
FACS Canto II BD Biosciences 
Freezer (-20°C) Kirsch 
Freezer (-80°C) Sanyo 
Fridge (4°C) Liebherr 
Ice machine AF100 Scotsman 
Inverted microscope Leica Microsystems 
LightCycler 480 Instrument Roche Diagnostics 
MACS manual cell separator Miltenyi Biotec 
Magnetic stirrer MR3001 Heidolph 
Micro Centrifuge Carl Roth 
Microwave oven Sharp 
Mini-vortex MS3 basic IKA 
Neubauer Chamber  Glaswarenfabrik Karl Hecht 
Orbital shaker 7-0031 NeoLab Migge 
PH meter 211 Sigma-Aldrich 
Roller Ortho Diagnostic Systems 
Rotator  Neolab 
SDS-PAGE power unit Power-Pac 200 Bio-Rad 
SDS-PAGE unit  VWR 
Spectrophotometer infinite M200 TECAN 
Thermomixer comfort Eppendorf 
Universal turning device VivaScience 
Veterinary anesthesia evaporator MIDMARK 
Vortex Genie 2 Scientific Industries 
Water bath VWB12 VWR 
X-ray film processor CAWOMEN 2000 IR CAWO Solutions 
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2.3 Buffers and solutions 
2.3.1 Running buffer for agarose gel electrophoresis 
1) 242 g Tris free base were dissolved in 750 ml ddH2O. 
2) 57.1 ml acetic acid and 100 ml of EDTA solution (0.5M) were added to the solution and 
the volume was adjusted to 1 L with ddH2O. 
3) 20 ml of the solution was dissolved in 980 ml of ddH2O to make 1x TAE buffer for 
agarose gel electrophoresis 
2.3.2 Buffers and solutions for cell fixation, immunohistochemical and 
immunofluorescent staining. 
2.3.2.1 Solution for cell fixation 
1) 40 g of paraformaldehyde (PFA) was dissolved in 700 ml of PBS.  
2) The pH was adjusted to 11.4 with 1 N NaOH. 
3) The solution was stirred at room temperature for 1 h to dissolve PFA completely.  
4) The pH was adjusted to 7.4 with HCl and the volume was adjusted to 1 L with PBS.  
5) The solution was filtered, aliquoted and stored at -20°C. 
2.3.2.2 Solution for cell permeabilization 
1) 2.5 ml of Triton X-100 was mixed with 500 ml of PBS. 
2) The solution was stirred by placing on top of a magnetic stirrer for 1 h. 
3) The solution was stored at room temperature. 
2.3.2.3 Blocking Solution  
1) 1.5 g BSA powder was weighed and poured into a 50ml falcon tube. 
2) 50 ml of PBS was added to dissolve BSA powder. 
3) The falcon tube was placed on a Tube Roller Mixers at 15-20 rpm/min overnight. 
4) The solution was stored at 4°C for no more than one month. 
2.3.2.4 Solution for diluting antibody 
Blocking solution prepared according to above protocol was diluted with PBS in a ratio of 1:3 
to make solutions for diluting antibody. 
2.3.2.5 Solution for washing 
1) 10 ml of Tween-20 was added to 90 ml of PBS. 
2) The PBS/Tween-20 solution was mixed by placing on top of a magnetic stirrer for 1 h. 
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3) 10 ml of the PBS/Tween-20 solution was mixed with 10 L of PBS to make washing 
solution. 
2.3.3 Buffers for SDS-PAGE and Western Blot 
2.3.3.1 10% APS 
1 g ammonium persulfate was weighed and dissolved in 10 ml of ddH2O, which was 
aliquoted and stored in -20°C. 
2.3.3.2 Running buffer for SDS-PAGE 
100 ml of 10x TGS was dissolved in 900 ml of ddH2O. 
2.3.3.3 Blotting buffer for SDS-PAGE 
1) 100 ml of 10x TGS solution and 200 ml of methanol were added to 600 ml of ddH2O. 
2) The final volume was adjusted to 1 L with ddH2O. 
2.3.3.4 Loading buffer for SDS-PAGE 
50 µl of β-mercaptoethanol was mixed with 950 µl of 2x Laemmli sample buffer. 
2.3.3.5 Blocking solution for SDS-PAGE 
1) 3 g of non-fat milk powder was dissolved in 20 ml of PBS. 
2) The final volume was adjusted to 50 ml with PBS. 
2.3.3.6 Antibody dilution solution for SDS-PAGE 
1 g of non-fat milk powder was dissolved in 20 ml of PBS and the final volume was adjusted 
to 100 ml with PBS. 
2.3.4 Buffer for flow cytometry analysis 
2.3.4.1 FACS buffer 
1) 10 ml of FCS was mixed with 1 L of PBS. 
2) Sodium azide was added to the solution, and the final concentration of sodium azide was 
adjusted to 0.1%. 
2.3.5 MACS buffer  
1) 2.5 g of BSA powder and 2 ml of 0.5 M EDTA were dissolved in 500 ml of PBS. 
2) The solution was mixed by shaking at room temperature for 3 h, and then it was filtered 
through the 0.22 µm filter. 
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2.3.6 Solution for cell cryopreservation 
DMSO was dissolved in FCS at the ratio 1:10, which was then filtered through a 0.22 µm 
filter. 
2.3.7 Buffer for RNA isolation 
20 µl of β-mercaptoethanol was added to 1 ml of the TRK buffer to make lysis buffer for 
RNA isolation. 
2.4 Animal techniques 
2.4.1 Mice used in the study 
Wild type BALB/c female mice at the age of 8-10 weeks were bought from Janvier Labs, 
and the mice were housed at least one week in animal core facility before performing 
injection. Stabilin-1 knockout (ko) in BALB/c female mice were generated by Dr. Kai 
Schledzewski (Department of Dermatology, Venerology and Allergy, Medical Faculty 
Mannheim, University of Heidelberg) and Prof. Bernd Arnold (German Cancer Research 
Center)
126
. 30 BALB/C stabilin-1 ko mice at the age of 8-12 weeks offered by Dr. Kai 
Schledzewski were used in the study. TS/A clones stably transfected with mChid1 (TS/A-SI-
CLP) and TS/A clones stably transfected with empty vector (TS/A-EV) were generated in our 
lab by previous PhD student (Nan Wang, PhD thesis 2014). The ethic approval numbers of 
murine tumor model (TS/A tumor in stabilin-1 ko mice) are 35-9185.81/G-115/07 and 35-
9185.81/G-208/10. The ethic approval number for isolating TAM from BALB/c mice injected 
by TS/A-EV and TS/A-SI-CLP cells is 35-9185.81/G-228/15.  
2.4.2 Preparation of tumor cells 
1) Freshly thawed TS/A-EV and TS/A-SI-CLP cells were passaged 2-3 times to maintain 
them in the exponential growth phase before performing tumor injection.  
2) 2X106 TS/A-EV and TS/A-SI-CLP cells were grown in RPMI complete medium 
supplemented with 400 µg/ml G418 until the cell confluence in T75 flasks reached 80-
90%. 
3) Tumor cells were harvested according to the standard protocol for adherent cells, and 
3X10
6 
cells were plated into a new T175 flask.  
4) The expression of SI-CLP protein in TS/A-EV and TS/A-SI-CLP cells was determined 
by performing immunofluorescent staining and Western Blot at the same time. 
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5) The medium was changed one day before performing in vivo injection.  
6) On the day of harvesting cells for tumor injection the cell confluence was 70-90%.  
7) The cells were washed once with PBS (without Ca2+, Mg2+). 
8) 3 ml of 1x Trypsin/EDTA solution was added to the T175 flask and incubated at 37°C 
for 2 min to detach the cells.  
9) 10 ml of RPMI complete medium was added to the flask for neutralizing the effect of 
trypsin.  
10) The cell suspension was collected and transferred to a 50ml falcon tube.  
11) The cells were pelleted after centrifugation at 1,300 rpm, 4°C for 5 min.  
12) The cell pellet was washed twice with PBS and re-suspended in 20 ml of PBS.  
13) The cell suspension was passed through 70 µm cell strainers to remove cell clumps. 
14) A 10 µl aliquot was applied for determining the total cell amount and cell viability with a 
Neubauer Chamber. Formula of quantification: cell quantity (cells/ml) = cell amount in 4 
quadrants/4 × dilution factor ×10
4
 
15) The cells were pelleted and re-suspended with an appropriate amount of PBS to reach a 
final concentration (25X10
6
 cells/ml PBS).  
16) The cell suspension was placed on ice and transported to the animal house in 5 min. 
2.4.3 Subcutaneous injection of tumor cells  
1) The hairs on right flank area of mice were shaved one day before injecting tumor cells. 
2) The mice were anesthetized by inhaling isoflurane. 
3) The mice were placed on the top of a mouse cage with the right flank upwards.  
4) The skin on the right flank of anesthetized mice was disinfected. 
5)  Loose skins of the right flank were lifted up by two fingers, and 100 µl of the cell 
suspension in a 1 ml insulin syringe was injected into one mouse subcutaneously. Any 
air-bubbles or leaking should be avoided during injection. The injection of TS/A-EV and 
TS/A-SI-CLP cells was as homogenous as possible.  
6) The mice were put back to the cage after recovering from anaesthesia. 
2.4.4 Measurement of tumor growth  
The tumor volume was measured on day 7, 10, 14, 18 and 21 after injection of tumor 
cells. The greatest longitudinal diameter (length), the greatest transverse diameter (width) and 
tumor thickness were measured by calliper. Tumor volume (in mm
3
) was calculated using the 
formula for an ellipsoid: Tumor volume = 0.52 × length × width × thickness 
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Mice were sacrificed by cervical dislocation on the day 21 post-injection. Tumor were 
excised and weighed. Freshly excised tumor tissues were used for isolating TAM or snap-
frozen in liquid nitrogen. Frozen tumor tissues were kept in a -80°C freezer and used for 
immunohistochemical and immunofluorescent staining.  
2.5 Cell Culture 
2.5.1  Cell line and primary cells 
Table 4. List of cell line and primary cells used in the study. 
Name of the cell line or primary cells Growth/cultivation medium 
(P/S: penicillin/streptomycin) 
Growth condition 
CD14+ human monocytes Macrophage SFM medium 37°C, 7,5% CO2 
Murine bone marrow cells 
DMEM supplemented with 10% FCS 
and 100 µg/ml P/S 
37°C, 7,5% CO2 
Murine TAM 
DMEM supplemented with 10% FCS 
and 100 µg/ml P/S 
37°C, 7,5% CO2 
SI-CLP transfected TS/A clones  
(P1D5, P1C8, P1F10, P2B7 and P2G7) 
 
RPMI medium supplemented with 10% 
FCS, 100 µg/ml P/S and 400 µg/ml 
G418 
37°C, 5% CO2 
Empty vector transfected TS/A clones  
(CL-1, CL-A1, CL-A3, CL-A4 and CL-A6) 
RPMI medium supplemented with 10% 
FCS, 100 µg/ml P/S and 400 µg/ml 
G418 
37°C, 5% CO2 
TS/A cells 
RPMI medium supplemented with 10% 
FCS and 100 µg/ml P/S 
37°C, 5% CO2 
2.5.2 Propagation of cells 
2.5.2.1 Harvesting adherent cells 
1) The medium in T75 flask was aspirated and 5 ml of PBS (without Ca2+ and Mg2+) was 
added to remove all traces of the serum containing trypsin inhibitors.  
2) 2 ml of 1x Trypsin/EDTA solution was added to the flask, which was incubated at 37°C 
for 3 min to detach the cells.  
3) 8 ml of RPMI complete medium was added to stop the reaction and all cells in 
suspension were collected. 
4) The cell suspension was centrifuged at 1,200 rpm for 8 min to pellet cells.  
5) The cell pellet was re-suspended in 1 ml of RPMI complete medium.  
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6) An appropriate aliquot of the cell suspension was applied for determining the cell 
amount. 
7) 2X106 tumor cells were plated in a new T75 flask for propagation. 
2.5.2.2 Cryopreservation of cells  
1) Tumor cells were harvested according to the protocol described above.  
2) After last centrifugation, an appropriate aliquot of the cell suspension was applied for 
determining the cell amount and cell viability.  
3) 3-5X106 tumor cells were re-suspended in 1 ml of frozen medium.  
4) The cell suspension was placed into an Mr. Frosty freezing container, which was stored 
at -80°C overnight and transferred to a liquid nitrogen tank for long-term storage. 
2.5.2.3 Thawing cells  
1) Frozen aliquot of tumor cells was taken out from a liquid nitrogen tank and thawed 
rapidly in a 37°C water bath. 
2) Thawed tumor cells were re-suspended in 10 ml of sterile PBS (without Ca2+ and Mg2+).  
3) The cell suspension was centrifuged at 1,200 rpm for 8 min to get rid of residual DMSO.  
4) The cell pellet was re-suspended in 10 ml of fresh complete medium and transferred to 
the sterile culture flask. 
2.5.3 Isolation of CD14+ human monocytes from buffy coats 
Fresh buffy coats in protective bags of 30 ml were provided by the German Red Cross 
Blood Donor Service Baden-Württemberg–Hessen. A unique number was given for each 
individual donor.  
1) 15 ml of Biocoll separating solution was poured into a 50ml falcon tube.  
2) The blood from the buffy coat package was poured into a sterile T75 flask and mixed 
with the same amount of PBS (without Ca2+ and Mg2+).  
3) 30 ml of diluted blood was slowly added to the falcon tube with Biocoll separating 
solution inside. 
4) The falcon tube was centrifuged at 420 RCF, 20°C for 30 min without breaks.  
5) Enriched peripheral blood mononuclear cells fraction (white ring) was collected in a new 
50ml falcon tube, which was filled with PBS until 50 ml and centrifuged at 420 RCF, 
20°C for 10 min with break.  
6) The supernatant was aspirated and the cell pellet was re-suspended in 5 ml of PBS.  
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7) The cell suspension was filled with PBS until 50 ml and centrifuged at 420 RCF, 20°C 
for 10 min.  
8) The supernatant was aspirated and the cell pellet was re-suspended again in 5 ml of PBS. 
The cell suspension was filled with PBS until 50 ml and a 10 µl aliquot was applied for 
cell counting.  
9) The cell suspension was centrifuged at 420 RCF, 20°C for 10 min.  
10) 30 ml of Percoll gradient solution was prepared by mixing 13.5 ml Percoll, 15 ml MEM 
Spinner modification and 1.5 ml 10x Earle´s salt solution in a 50ml falcon tube. 
11) The supernatant of cell suspension was aspirated and the cell pellet was re-suspended in 
3 ml of PBS.  
12) The cell suspension was carefully added on top of the Percoll gradient solution in 50ml 
falcon tube, which was centrifuged at 420 RCF, 20°C for 30 min without breaks.  
13) The upper layer containing the mononuclear cells was carefully collected and transferred 
into a new 50ml falcon tube.  
14) The total volume in falcon tube was filled up to 50 ml with PBS and the falcon tube was 
centrifuged at 420 RCF, 20 °C for 10 min with breaks.  
15) The supernatant was aspirated and the cell pellet was re-suspended in 5 ml of PBS. 
16) The cell suspension was transferred into a 15ml falcon tube and the total volume of cell 
suspension was filled up to 10 ml. 
17) 10 µl of cell suspension was applied for cell counting and the rest of cell suspension was 
centrifuged at 420 RCF, 20 °C for 10 min 
18) The supernatant was carefully aspirated and the cell pellet was re-suspended in 95 µl of 
MACS buffer + 5 µl CD14 micro beads per 107 cells. 
19) The cells were incubated at 4°C for 20 min on a rotator.  
20) The final volume was made up to 10 ml with MACS buffer and centrifuged at 420 RCF, 
20°C for 10 min.  
21) The cell pellet was re-suspended in 1 ml of MACS buffer.  
22) An LS separation column was placed in the magnetic separation unit and washed once 
with 3 ml of MACS buffer.  
23) A fresh collecting tube was placed beneath the LS separation column and the cell 
suspension was added to the LS column.  
24) The LS column was washed three times with 3 ml of MACS buffer before removing 
from magnetic separation unit.  
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25) The column was placed on top of a fresh 15ml falcon tube and 5 ml of MACS buffer was 
added to elute CD14+ monocytes from the column. 
26) 10 µl of aliquot was applied for cell counting and the cell suspension was centrifuged at 
420 RCF, 20°C for 10 min.  
27) The cell pellet was re-suspended in appropriate macrophage SFM medium to reach a 
final concentration of 1X106 cells/ml. 
2.5.4 Isolation of bone marrow cells from BALB/c female mice. 
1) BALB/c female mice were sacrificed by cervical dislocation.  
2) The abdominal part of the mice was sterilized with 70% ethanol. 
3) The legs close to the hip were cut off with scissors. 
4) The skin was removed from the legs and the foot link was broken. 
5) The muscles were totally removed from the bones with scissors and forceps. The femur 
and tibia were separated after the knee joint was broken.  
6) The bones were sterilized with 70% ethanol for 1 min and transferred to a Petri dish 
filled with cold PBS. 
7) A hole was made on both ends of the bones to allow flushing of bone marrow with the 
needle of a syringe.  
8) A 10ml syringe coupled with a 22 G needle was filled with PBS and bone marrow was 
expelled from both sides of the bone into a 50ml falcon tube. 
9) The cells were mixed by pipetting 5-8 times to break cell aggregates and passed through 
a 70 µm Cell Strainer.  
10) The cell suspension was centrifuged at 400 RCF for 10 min and the cell pellet was re-
suspended in 1 ml of Red Blood Cell Lysis Buffer.  
11) The cell suspension was transferred to a new 15ml falcon tube and incubated at room 
temperature for 2 min. 
12) 3 ml of DMEM complete medium was added to the cell suspension, followed by 
centrifuging samples at 400 RCF for 6 min. 
13) The cell supernatant was aspirated and the cell pellet was re-suspended in 5 ml of 
DMEM complete medium supplemented with 30 ng/ml M-CSF.  
14) 10 µl of the cell suspension was applied for cell counting and the cell suspension was 
adjusted to 1X106 cells/ml with murine bone marrow medium.  
15) The cells were plated in 6 wells plate and cultured for four days in murine bone marrow 
medium at 37°C in 7.5% CO2 incubator. 
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2.5.5 Isolation of murine TAM  
TAM were isolated from mammary adenocarcinoma tumors generated by subcutaneous 
injection of 2.5X10
6
 TS/A-EV and TS/A-SI-CLP cells in BALB/c female mice. 2.5 mg 
DNase I and 8.5 mg collagenase IV were dissolved in 10 ml of Reduced Serum Medium, 
which was filtered through a 0.22 µm filter into a 15ml falcon tube. 10 ml of enzyme mix was 
applied for digesting up to 2 g TS/A tumors.  
1) Mice were anaesthetized with isoflurane and sacrificed by cervical dislocation. 
2) The hair over the tumors was shaved and the area was disinfected. 
3) The tumor was carefully excised with scissors and placed in a 10 cm Petri dish. 
4) The tumor was carefully skinned and weighed. 
5) The necrosis area was removed from the tumor tissue, and the rest of tumor was chopped 
to tiny pieces in the Petri dish. 
6) Chopped tumor pieces were transferred to a falcon tube filled with the corresponding 
amount of enzyme mix.   
7) Falcon tube containing tumor tissues was incubated at 37°C for 1.5 h on a rotating 
shaker. 
8) Digested tumor tissues were passed through a 100 μm Cell Strainer into a 50ml falcon 
tube, and the cell strainer was rinsed once with cold PBS. 
9) The total volume of digested tumor tissue was adjusted to 50 ml with cold PBS. 
10) The falcon tube was centrifuged at 4°C, 1,600 rpm for 10 min.  
11) The cell supernatant was aspirated and the cell pellet was re-suspended in 10 ml of cold 
MACS buffer. 
12) The cell suspension was passed through a 40 μm cell strainer into 50ml falcon tubes and 
counted with a Neubauer Chamber. 
13) The cell suspension was centrifuged at 1,500 rpm, 4°C for 10 min.  
14) The cell supernatant was carefully aspirated and the cell pellet was re-suspended in 10 
ml of cold MACS buffer. 
15) The falcon tubes were centrifuged at 1,500 rpm, 4°C for 10 min. 
16) The cell supernatant was aspirated and the cell pellet were re-suspended in 90 µl of 
MACS buffer per 107 total cells. 
17) 10 μl of mouse CD11b microbeads were added to the cell suspension per 107 total cells.  
18) The cell suspension was mixed well and incubated at 4°C for 15 min. 
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19) 2 ml of MACS buffer per 107 cells was added to the cell suspension, which was 
centrifuged for 10 min at 1,500 rpm, 4°C. 
20) The cell supernatant was aspirated and up to 108 cells was re-suspended in 500 µl of 
MACS buffer. 
21) The LS columns were placed in the magnetic field of a MACS separator, and 3 ml of 
MACS buffer was added to rinse each column. 
22) The cell suspension was applied on the column, and the column was washed three times 
once the column reservoir was empty. 
23) The column was removed from the MACS separator and placed on a clean 15 ml falcon 
tube. 
24) 5 ml of MACS buffer was pipetted on the column to flush CD14 positive cells. 
25) 10 μl of the cell suspension were taken for counting cells in a Neubauer chamber after 
MACS separation. 
26) The cell suspension was centrifuged at 1,300 rpm 4°C for 8 min. 
27) The supernatant was aspirated and pre-warmed DMEM complete medium was added to 
get a final concentration of 1X106/ml medium. 
28) 4X106 isolated TAM were added to one well of 6 wells plates, which was placed in 
37°C, 5% CO2 incubator. 
29) After 30 min, non-adherent cells in 6 wells plates or Petri dishes were washed away by 
adding DMEM medium.  
30) 350 μl of RNA lysis buffer was added to adherent TAM in one well of 6 wells plates, and 
the RNA lysates were used for RNA isolation and Microarray gene chip analysis. 
Moreover, 2X106 TAM was seeded on top of a coverslip and used for staining CD68 
protein. 
31) 4X106 TAM were maintained in DMEM complete medium for 16 h, and the conditioned 
supernatant from TAM were harvested. 
2.5.6 Isolation of spleen T cells from BALB/c mice 
1) The mice were sacrificed by cervical dislocation. 
2) The abdominal part of the mice was sterilized with 70% ethanol. 
3) The abdominal cavity was opened and the whole spleen was taken out. 
4) The spleen tissue was cut into small pieces with a fine scissor and smeared with the end 
of a 5ml syringe. 
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5) The tissue suspension was passed through a 70 µm Cell Strainer, which was washed 
three times with sterile PBS. 
6) The cell suspensions were centrifuged at 400 RCF for 10 min and the cell pellet was re-
suspended in 1 ml of red blood cell lysis buffer. The cell suspension was transferred to a 
15ml falcon tube and incubated at room temperature for 2 min. 
7) 8 ml of RPMI medium was added to the cell suspension, which was centrifuged for 6 
min at 400 RCF. 
8) The supernatant was aspirated after centrifugation and the cell pellet was re-suspended in 
5 ml of RPMI medium.  
9) A 10 µl of aliquot was taken for cell counting and the cell suspension was centrifuged at 
400 RCF for 6 min. 
10) The supernatant was aspirated and the cell pellet was re-suspended in 40 µl of FACS 
buffer per 107 total cells. 
11) 10 µl of biotin conjugated antibody cocktail was added to the cell suspension per 107 
total cells. 
12) The cell suspension was incubated on ice for 5 min, and then 30 µl of FACS buffer was 
added per 107 total cells. 
13) 20 µl of anti-biotin microbeads was added to the cell suspension per 107 total cells. 
14) The cell suspension was fully mixed and incubated on ice for 10 min. 
15) The LS columns were placed in the magnetic field of a MACS separator, and 3 ml of 
MACS buffer was added to rinse each column. 
16) The cell suspension was added to each column, which was washed three times by adding 
3 ml of MACS buffer. 
17) Spleen T cells were eluted from the column and collected in a 15ml falcon tube. 
18) The falcon tube was centrifuged at 4°C, 1,300 rpm for 8 min. 
19) The cell pellet was re-suspended in 1 ml of RPMI medium, and 10 µl of the cell 
suspension was used for determining the cell amount. 
20) The purity of mouse spleen T cells was determined by staining CD3 antigen and 
analyzed by flow cytometry. 
21) The spleen T cells were plated in 6 wells plates and maintained at 37°C, 7.5% CO2 
incubator for 4 h before performing chemotaxis assay. 
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2.6 Immunological techniques 
2.6.1 Primary antibodies 
Table 5. List of primary antibodies used in this study. (st: stock concentration; wd: 
working dilution; NA: Not Applicable). 
Antigen name Catalog 
number 
Company 
(St) 
Species, 
 
IF wd WB wd IHC wd  FACS wd 
CD206 MCA2235GA AbD-Serotec 
st: 1.0 mg/ml 
Rat-IgG2a N/A N/A 1:1000 N/A 
CD3 14-0031-85 eBioscience 
st: 0.5 mg/ml 
Armenian 
Hamster IgG 
N/A N/A 1:200 N/A 
CD31 MCA2388 AbD-Serotec 
st: 1.0 mg/ml 
Rat-IgG2a N/A N/A 1:400 N/A 
CD3-APC 100312 BioLegend   
st: 0.5 mg/ml 
Rat IgG2c N/A N/A N/A 1:100 
CD4 biotin 100507 BioLegend  
st: 0.5 mg/ml 
Rat IgG2a N/A N/A 1:200 N/A 
CD68 SM1550P Acris                 
st: 1.0 mg/ml 
Rat IgG2a                        1:200 N/A 1:200 N/A 
CD8a 558733 eBioscience 
st: 0.5 mg/ml 
Rat IgG2a N/A N/A 1:200 N/A 
FoxP3 biotin 135773 eBioscience 
st: 0.5 mg/ml 
Rat IgG2a N/A N/A 1:200 N/A 
Gr-1 Ab25377 Abcam        
st: 0.5 mg/ml 
Rat IgG2b N/A N/A 1:400 N/A 
LYVE-1 biotin 103-PA50AG Relia-tech     
st: 1.0 mg/ml 
Rabbit  N/A N/A 1:400 N/A 
PD-1 AF1021-SP Techne 
Corporation           
st: 0.2 mg/ml 
Goat IgG N/A N/A 1:200 N/A 
SI-CLP 1B8  Our 
laboratory 
Rat-IgG2a 
Hybridoma 
supernatant 
1:3 1:3 1:3 N/A 
Siglec-F 552125 eBioscience 
st: 0.5 mg/ml 
Rat IgG2a N/A N/A 1:200 N/A 
Stabilin-1 RS-1 Our 
laboratory 
Rabbit IgG 
Immunserum 
N/A N/A 1:800 N/A 
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2.6.2 Secondary antibodies, conjugates, and fluorescent dyes 
Table 6. List of secondary antibodies, conjugates and fluorescent dyes used in the study. 
(st: stock concentration; wd: working dilution; NA: Not Applicable) 
Antibody conjugated Catalog number Company, (st) IF (wd) WB (wd) IHC (wd) 
Alexa Fluor 488 
conjugated donkey anti-
rat IgG 
712-546-153 
Jackson 
ImmunoResearch       
st: 1.4 mg/ml 
1:400 NA NA 
DAPI 236276 
Roche Diagnostics                       
st: 1 mg/ml 
1:1000 NA NA 
DRAQ5 4084 
Cell Signaling 
Technology              
st: 5mM 
1:1000 NA NA 
HRP conjugated  
streptavidin 
016-030-084 
Jackson 
ImmunoResearch     
st: 1.0 mg/ml 
NA NA 1:400 
HRP conjugated goat 
anti-Armenian Hamster 
IgG 
Sc-2443 
Santa Cruz 
Biotechnology            
st: 0.4 mg/ml 
NA NA 1:200 
HRP conjugated goat 
anti-rabbit IgG 
R1364 
Acris Pharmaceutics 
st: 1.0mg/ml 
NA NA 1:400 
HRP conjugated goat 
anti-rat IgG 
Sc-2065 
Santa Cruz 
Biotechnology           
st: 0.4 mg/ml 
NA 1:5000 1:400 
 
2.6.3 Immunofluorescent staining and confocal microscopy analysis 
2.6.3.1 Cell fixation with PFA 
All procedures were performed at room temperature. The following protocol was used to 
fix cells grown on coverslips in 6 wells plates. 
1) The cells in 6 wells plates were washed two times with 1 ml of PBS. 
2) The cells were fixed with 1 ml 2% PFA in PBS for 10 min. 
3) PFA solution was aspirated. 
4) 2 ml of 0.5% Triton X-100 in PBS was added to each well. 
5) 0.5% Triton X-100/PBS solution was aspirated 15 min later.  
6) The cells were fixed with 1 ml of 4% PFA in PBS for 10 min. 
7) PFA solution was aspirated and the cells were washed 4 x 10 min with PBS on a shaker. 
8) Plates were dried in the hood. 
9) Plates were sealed with Parafilm and stored at -80°C. 
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2.6.3.2  Immunofluorescent staining  
1) The cells in 6 wells plates were washed two times with 2 ml of PBS and each washing 
was performed for 5 min on a shaker. 
2) The cells were washed with 1 ml of 0.1 % Tween 20 in PBS for 30 sec. 
3) The cells were incubated with 1 ml of 3% BSA in PBS for 1 h and then briefly washed 
with 1 ml of 0.1 % Tween 20 in PBS for 30 sec. 
4) Primary antibody was diluted in 1% BSA/PBS solution according to the Table 7. 
5) 100 µl of primary antibody solution were dropped exactly on top of each coverslip to 
cover the cells area and incubated with the cells at room temperature for 1.5 h. 
6) The cells were washed 3 x 5 min with PBS on a shaker. 
7) The cells were washed briefly with 2 ml of 0.1 % Tween 20 in PBS for 30 sec. 
8) Secondary antibody along with DRAQ5 for nuclear staining was diluted in 1% BSA/PBS 
and 100 µl of secondary antibody solution was dropped exactly on the top of each 
coverslip. 
9) The cells were incubated with secondary antibody solution for 45 min at room 
temperature. During and after this process plates were kept in the dark environment.  
10) The cells were washed 4 x 5 min with PBS on a shaker.  
11) A drop of fluorescent mounting medium was added to each glass slide and the coverslips 
with stained cells were in contact with mounting medium directly without causing visible 
air bubbles.  
12) The mounted samples were stored at 4°C in darkness for at least 24 h before analyzed 
using Confocal Laser Scanning Microscope.  
2.6.3.3 Confocal microscopy analysis 
Confocal microscopy analysis was performed using a Leica Microsystems TCS SP8 
laser scanning spectral confocal microscope, equipped with a 63×1.32 objective. As a source 
of excitation an argon laser emitting at 488 nm, a krypton laser emitting at 568 nm and a 
helium/neon laser emitting at 633 nm were used. Data were acquired and analyzed with Leica 
Microsystems Confocal Software. 
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2.6.4 Immunohistochemical analysis of frozen tissue sections 
2.6.4.1 Preparation of frozen tissue sections 
1) TS/A tumor tissues were taken out from -80°C freezer and placed in -20°C freezer for 20 
min. 
2) Cryostat microtome was cooled down to -22°C. 
3) A small amount of O.C.T compound was added on top of a cryostat object disk that was 
at room temperature. 
4) Frozen tumor tissues were positioned in the center of the object disk and transferred back 
to microtome. 
5) Enough O.C.T compound was added to embed the whole tumor tissue before the object 
disk become solid. 
6) The disk was placed in the object disk holder of the microtome and the set screw was 
tightened to fix the object disk. Enough space was left between the block and the 
microtome blade.  
7) The ratchet was disengaged from the micrometer gear and the block was moved toward 
the blade edge with forward button. 
8) Engage the ratchet on the micrometer gear and turn the flywheel with right hand to cut 
the tissues until a full section of the specimen was visible. 
9) The thickness of cutting section was set to 5 μm and the first 3-5 sections were 
discarded. 
10) The sections were unfolded with the paint bush and picked up with Super Frost 
Microscope Slides. 
11) The sections were stored in -80°C freezer until immunohistochemical staining. 
2.6.4.2 Staining process 
All staining procedures were performed at room temperature. 
1) Frozen tissue sections were fixed with acetone for 10 min and dried in the hood for 20 
min. 
2) A ring around the section was drawn with a DAKO Pen. 
3) The fixed tissue sections were washed with 0.1% Tween-20 in PBS for 5 min. 
4) The tissues sections were incubated with peroxide blocking solution for 10 min.  
5) The tissue sections were washed with 0.1% Tween-20 in PBS for 30 sec. 
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6) Streptavidin/biotin blocking kit was applied before the staining when primary antibody is 
biotinylated. The tissue sections were incubated with streptavidin solution for 15 min.  
7) The tissue sections were washed 2 x 5 min with PBS on a shaker.  
8) The tissue sections were incubated with biotin solution for 15 min.  
9) The tissue sections were washed 3 x 5 min with PBS on a shaker.  
10) The tissue sections were incubated with 3% BSA in PBS for 1 h. 
11) The tissue sections were washed with 0.1% Tween-20 in PBS for 30 sec. 
12) Primary antibody was diluted in 1% BSA/PBS solution and 100 µl of primary antibody 
solution was added to cover each tissue. 
13) The tissue sections were incubated with primary antibody for 1.5 h. 
14) The tissue sections were washed 3 x 5 min with PBS and then washed with 0.1% Tween-
20 in PBS for 30 sec on a shaker. 
15) Secondary antibody was diluted in 1% BSA/PBS solution and 100 µl antibody solution 
was added to cover each tissue. 
16) The tissue sections were incubated with the secondary antibody solution for 45 min. 
17) The tissue sections were washed 3 x 5 min with PBS on a shaker.  
18) The tissue sections were incubated with AEC chromogen substrate for 5-15 min. 
19) Development of the reaction was terminated by washing the tissue sections with PBS for 
5 min. 
20) The tissue sections were immersed in Mayer’s hematoxylin solution for 1 min (Mayer’s 
hematoxylin solution should be filtered before usage). 
21) The tissue sections were washed with tap water until blue colors faded away. 
22) The tissue sections were mounted with Faramount mounting medium and covered with 
cover glasses. Stained samples were stored at room temperature. 
2.6.4.3 Large tissue scanning technique 
1) Stained tumor tissue mounted on top of object glasses were sequentially scanner under 
10x objective of Nikon Eclipse Ni-E microscope (JAPAN).  
2) The settings for taking sequential image acquisitions were the same for all sections 
stained with one specific marker. 
3) The entire image was assembled with NIS Elements Imaging software. 
4) The entire image of whole tumor specimen was analyzed with ImageScope software 
(version 12.1.0.5029, Aperio Technologies, Inc, 2003-2013, Wetzlar, 35578, Germany).  
5) Necrosis area and overlay area was excluded with negative selection tool of ImageScope. 
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6) The positivity of staining was calculated by Positive Pixel Count Algorithm (dividing the 
number of positive pixels by the total number of pixels in the selected area). 
7) The analysis for each picture was performed by two independent observers from our 
laboratory. 
2.6.5 Immunoprecipitation 
1) 10 µl of Protein G Sepharose beads required for each reaction were washed 3 x 5 min 
with PBS/0.1% Tween 20 solution and centrifuged at 6,000 rpm, 4°C for 5 min.  
2) 200 µl of rat anti-SI-CLP antibody (1B8), 2 µg of rat IgG2a in 200 µl of PBS and 200 µl 
of PBS was mixed with 800 µl of PBS, which was added to pelleted Protein G Sepharose 
beads. The mixture was incubated on a rotator at 4°C overnight. 
3) The Protein G Sepharose beads conjugated with antibody were centrifuged at 6,000 rpm, 
4°C for 5 min. 
4) The supernatant was carefully aspirated, leaving 30-50 µl of liquid on top of pelleted 
Protein G Sepharose beads.  
5) The Protein G Sepharose beads conjugated with antibody were washed 3 x 5 min with 
PBS/0.1% Tween 20 solution, followed by centrifugation at 6,000 rpm, 4°C for 5 min. 
6) 20 µl of conditioned supernatant of BHK-21 recSFV/SI-CLP cells were mixed with 800 
µl of DMEM medium, which was added to the Protein G Sepharose beads.  
7) The mixture was incubator on a rotator at 4°C for 3 h. 
8) The mixture was centrifuged at 6,000 rpm, 4°C for 5 min. 
9) The supernatant was collected in a 1.5 ml of Eppendorf tube, and the Protein G 
Sepharose beads were washed three times with PBS, followed by centrifugation at 6,000 
rpm, 4°C for 5 min. 
10) The supernatant and Protein G Sepharose beads conjugated with antibody were dissolved 
in the same amount of 2x Laemmli sample buffer, which was heated at 95°C for 3 min 
before loading for Western Blot analysis. 
2.6.6 Western blot analysis 
1) The gel casting unit was assembled and its integrity was tested by adding 20 ml of 
ddH2O to the gap of the two glass plates. Separating gel was prepared according to the 
Table 8. 
2) Freshly prepared 10% separating gel was poured between the two glass plates to cover 
80% of the gel casting unit.  
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3) 500 µl of 100% methanol was added immediately on top of the separating gel to get a 
level top. 
4) The methanol was dumped after separating gel was polymerized and washed two times 
with ddH2O. 
5) Stacking gel was prepared according to the Table 8 and poured on top of the separating 
gel. 
6) A comb was inserted immediately into the stacking gel to form wells. 
7) After the stacking gel polymerized, the gel casting unit was placed in an electrophoresis 
unit filled with 1×TGS running buffer.  
8) The comb was carefully removed without causing any air-bubbles or twisting the gel-
walls. 
9) Samples were mixed with the same volume of 2×Laemmli sample buffer supplemented 
with β-mercaptoethanol. 
10) The samples were heated at 95°C for 3 min, and they were centrifuged briefly before 
loading.  
11) 20 µl of sample was added to each well using a micro syringe.  
12) Electrophoresis was performed at a constant current of 15-50 mA per gel until the 
bromophenol blue reached the bottom of the gel.  
13) The gel was carefully removed from the glass plates and placed in a plastic container 
filled with blotting buffer. Filter papers and a nitrocellulose membrane were adjusted to 
the gel size and immersed into the blotting buffer. 
14) The Western Blot cassette was arranged in the following order: spongy pad / 2 filter 
papers / gel / Nitrocellulose membrane / 2 filter papers / spongy pad.  
15) Air bubbles were removed by gently rolling a glass rod over the top. The cassette was 
tightened and placed in a blotting apparatus filled with blotting buffer, with the 
membrane towards the positive side of the gel. 
16) Blotting was carried out at 250 mA for 3 h.  
17) The cassette was taken out from the blotting apparatus and the membrane was placed in 
a plastic container filled with PBS.  
18) The membrane was rinsed with PBS and stained with Ponceau S solution for 10 min to 
visualize the protein bands. 
19) The membrane was washed with ddH2O until the red dye was invisible. 
20) The membrane was incubated with 6% milk in PBS at room temperature for 1 h. 
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21) The membrane was incubated with primary antibody diluted in 1% milk/PBS at 4°C with 
shaking overnight. 
22) The membrane was shortly washed with 0.1% Tween 20 in PBS, and then it was washed 
4 x 5 min with 0.1% Tween 20 in PBS at room temperature on a shaker with 5 min.  
23) Species specific secondary antibody was diluted in 1% milk/PBS, which was added to 
cover the membrane. 
24) The membrane was incubated at room temperature for 1 h with shaking. 
25) The membrane was washed with 0.1% Tween 20 in PBS for 30 sec, and then it was 
washed 4 x 10 min at room temperature on a shaker. 
26) Western HRP substrate from Luminata Forte was added to cover the membrane, which 
was incubated at room temperature for 3 min.  
27) The membrane was packed in a plastic film and developed in an X-ray film processor to 
display protein band. 
Table 7. Composition of acrylamide gels. 
Ingredients 10% Separating gel/10ml 5% Stacking gel/ 5ml 
ddH2O 4.0 ml 3.4 ml 
1.5 M Tris (pH 8.8) 2.5 ml 0.63 ml 
10 % APS 0.1 ml 0.05 ml 
10 % SDS 0.1 ml 0.05 ml 
30% Acrylamide mix 3.3 ml 0.83 ml 
TEMED 0.004 ml 0.004 ml 
 
2.6.7 Flow cytometry analysis 
All cell staining procedures were performed in FACS tubes. All centrifugation after 
washing steps were performed at 400 RCF, for 4 min at room temperature. Freshly isolated 
naive T cells from spleen tissue of BALB/c mice were applied for analyzing the purity of T 
cells. 
1. Freshly isolated naive T cells were washed once with 1 ml of FACS buffer.  
2. 1X106 cells were re-suspended in 100 µl of FACS buffer.  
3. 1 µl of Fc block (BD Biosciences) was added to the samples and incubated for 5 min at 
4°C. 
4. 1 µg APC conjugated rat anti-CD3 IgG2c antibody diluted in 100 µl of FACS buffer was 
added to the sample and incubated for 30 min at 4°C. 
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5. Samples were washed two times with 500 µl FACS buffer. 
6. Cells were re-suspended in 200-300 µl FACS buffer before measurement. 
7. Samples were analyzed using a BD FACS Canto II. 
2.7 RNA related methods 
2.7.1 Isolation of total RNA  
The E.Z.N.A. total RNA kit I from Omega was used for RNA isolation. 
1) 350 µl of RNA lysis buffer was added to 3-5X106 cells. 
2) The cell lysates were completely disrupted by passing through a Nr.19 needle combined 
with a 10ml syringe 5-10 times.  
3) 350 µl of 70% ethanol were added to the cell lysates and mixed well by pipetting up and 
down 5-10 times.  
4) The sample was added to a RNA spin column placed in a 2ml collection tube without 
touching the membrane.  
5) The RNA spin column was centrifuged for 1 min at 10,000 RCF, and the flow-through 
was discarded. 
6) The RNA spin column was washed once by adding 500 µl of wash buffer I, followed by 
washing twice in 500 µl wash buffer II.  
7) The final flow-through was discarded, and a new 2 ml collection tube was placed under 
the column. 
8) The RNA spin column was centrifuged for 2 min at 16,000 RCF to dry the matrix 
completely. 
9) The RNA spin column was placed in a fresh RNase free Microfuge tube after the last 
centrifugation.  
10) 50 µl of RNase free water preheated at 70°C was added to elute RNA, followed by 
centrifuging the tube at 16,000 RCF for 2 min. 
11) The RNA concentration was determined by measuring the absorption peak at 260 nm 
wavelength.  
12) The quality of RNA samples was analyzed by electrophoresis in the 1% agarose gel. 
13) RNA samples were stored at -80°C. 
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2.7.2 First strand cDNA synthesis  
The RevertAid H Minus First Strand Synthesis Kit from Fermentas was used for cDNA 
synthesis.  
1) 1 µl of 10x DNase I buffer with MgCl2 (Fermentas) was added to each RNA sample (up 
to 1 µg) and mixed well by pipetting. 
2) 1 µl of RNase free DNase I (Fermentas) was added to the sample, and the total volume 
of each sample was adjusted to 12 µl with RNase free water.  
3) The sample was incubated at 37°C for 40 min to digest possible fragments of genomic 
DNA, and then DNase was inactivated by incubating at 70°C for 10 min. 
4) 1 µl of Oligo DT primer was added to the sample and mixed by tapping the Eppendorf 
tube gently.  
5) The sample was incubated at 70°C for 5 min. 
6) Each cDNA reaction mixture was prepared by mixing 4 µl of reaction buffer (5x) with 1 
µl of RiboLock RNase inhibitor, 2 µl of dNTP Mix (10M) and 1 µl of reverse 
transcriptase. 
7) 8 µl of cDNA reaction mixture was added to each sample, which was mixed and spin 
down before transferring back to Thermoblock. 
8) The sample was incubated at 42°C for 60 min and then at 70°C for 10 min. 
9) The cDNA samples were diluted 10 times with RNase free water for performing real-
time PCR analysis. 
2.7.3 Real-time PCR with TaqMan probes 
Primers and dual-labeled probes purchased from MWG Biotech are shown from 5’ to 3’ 
in the Table 9. Gene expression assay for mouse IL-10, TGF- β and VEGF-A were purchased 
from Thermo Fisher Scientific company. Probe of target gene contained FAM on the 5’ end 
and a BHQ1 quencher on the 3’ end of the sequence. Probe of β-actin gene contained JOE on 
the 5’ end and a BHQ1 on the 3’ end of the sequence. Each cDNA sample was analyzed in 
triplicates. The expression of target gene in each sample was normalized with the expression 
of β-actin gene in the same sample. 
Each reaction mixture for real-time PCR was prepared by mixing:  
1) 5 µl of TaqMan Gene Expression Master mix  
2) 0.5 µl of 20 x TaqMan Assay 
3) 1 µl of diluted cDNA sample  
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4) 3.5 µl of ddH2O. 
Amplification was performed using a Roche LightCycler 480 instrument. The following 
program was used:  
1) Denaturation: at 95°C for 10 min.  
2) Annealing and elongation for 1 min at 60°C, followed by denaturation at 95°C for 15 
sec; 50 cycles.  
3) Cooling: 37°C for 1 min. 
Table 8. List of primers used for real-time PCR analysis. 
Primers and number  Sequence (5’-3’) Application 
Mouse β-actin Forward AGC CAT GTA CGT AGC CAT CCA RT-PCR 
Mouse β-actin Reverse TCT CCG GAG TCC ATC ACA ATG RT-PCR 
Mouse β-actin Probe TGT CCC TGT ATG CCT CTG GTC GTA CCA C RT-PCR 
Mouse CD163 Forward GTGTGACATGTTCTGATGGA RT-PCR 
Mouse CD163 Reverse TCTTCCCAGTCAGCTTCT RT-PCR 
Mouse CD163 Probe TCTCCACCTCCACAATGCCAGCAC RT-PCR 
Mouse CD206 Forward TGCTTTAACCTGGCATCAG RT-PCR 
Mouse CD206 Reverse GGAACTGGTTAATCCTGTGAG RT-PCR 
Mouse CD206 Probe TGAGTGTCACGGAGATCCACGAGCA RT-PCR 
Mouse IL-1β Forward CTTTGAAGAAGAGCCCATCC RT-PCR 
Mouse IL-1β Reverse TTCATCTCGGAGCCTGTAG RT-PCR 
Mouse IL-1β Probe CCTGCTGGTGTGTGACGTTCCCAT RT-PCR 
Mouse IL-6 Forward GAGGATACCACTCCCAACAGACC RT-PCR 
Mouse IL-6 Reverse AAGTGCATCATCGTTGTTCATACA  RT-PCR 
Mouse IL-6 Probe TGTCTATACCACTTCACAAGTCGGAGGCT RT-PCR 
Mouse LYVE-1 Forward GACTCTGGATTGGACTCAAC RT-PCR 
Mouse LYVE-1 Reverse CTCTGATGATGGACTTCCTG RT-PCR 
Mouse LYVE-1 Probe AGTGTACGCAGTGGTTGGCAGTGG RT-PCR 
Mouse stabilin-1 Forward TACTGTTACCGCGTGCAAGACG RT-PCR 
Mouse stabilin-1 Reverse ATTGGCATAGCCCAGCAGCATC RT-PCR 
Mouse stabilin-1 Probe TCTTGGCCGCCACTGCCAACTTCTCCACCTTCTAT RT-PCR 
Mouse TNF-α Forward CTATGTCTCAGCCTCTTCT RT-PCR 
Mouse TNF-α Reverse GGAACTTCTCATCCCTTTG RT-PCR 
Mouse TNF-α Probe CAGTAGACAGAAGAGCGTGGTGGC RT-PCR 
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2.8 Migration Assay 
6.5 mm Transwell with 5 μm or 8 μm pore polycarbonate membrane inserts (Corning) 
were used for performing migration assay. Purified SI-CLP protein derived from HEK-293 
cells used for stimulation was purchased from Cusabio (Wuhan, China), and SI-CLP 
containing supernatant derived from alphavirus infected BHK-21 cells was provided by Dr. 
Anna Zajakina (Department of Protein Engineering, Biomedical Research and Study center, 
Riga, Latvia). 
Table 9. Migration model used in the study. 
Cell types 
Cell 
amount 
Migration buffer 
Membrane 
size (μm) 
Migration 
time (h) 
Chemokines 
CD14+ human monocytes 5x10
5
 
Macrophage 
SFM 
5 3 
Human 
CCL-2 
Mouse bone marrow derived 
macrophages 
5x10
5
 RPMI 5 3 
Murine 
CCL-2 
Mouse naive T cells 5x10
5
 RPMI 5 3 
Murine 
CCL19 
TS/A-EV and TS/A-SI-CLP cells 5x10
5
  RPMI 8 16 FCS 
 
1) Cells were re-suspended in migration buffer at a concentration of 5X106/ml according to 
the Table 10. 
2) 600 µl of migration buffer was added into the lower chamber without causing any visible 
air bubbles. 
3) 100 µl of the cell suspension was added in the top well of each Transwell carefully 
without touching the membrane. 
4) The whole Transwell plate was incubated at 37°C, 5% CO2 for 3 or 16 h. 
5) The medium in the top well was aspirated and a wet cotton swab was used to remove the 
cells on the upper side of each insert that had not migrated yet. 
6) The inserts were transferred to 24 wells plates with 800 µl of ice cold methanol (100%) 
inside. 
7) The 24 wells plates were placed in a -30°C freezer for 5 min. 
8) Methanol was aspirated and the inserts were washed three times in ddH2O for 10 min. 
9) Migrated cells at the lower side of inserts were stained with 1 ml of DAPI solution 
(prepared in PBS at 1: 1000 dilutions) for 5 min at room temperature. 
10) The inserts were washed 3 x 5 min in ddH2O. 
11) The upper surface of each insert was cleaned again by a wet cotton swab to get rid of 
residual non-migrated cells. 
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12) One drop of fluorescent mounting medium was added on top of a Super Frost object 
slide.  
13) The membrane of whole insert was cut off carefully and placed on Super Frost object 
slides with migrated cells towards the mounting medium directly. 
14) A 22 mm x 22 mm coverslip was applied for covering the membrane. The slides were 
dried at 4°C cooling room and protected from light.  
15) 10 random images were taken for each slide under the aid of a fluorescent microscope 
equipped with a 32x objective. The mean migrated cells for each reaction were 
calculated via counting the cells in each image.  
2.9 Proliferation assay 
The Click-iT® EdU Alexa Fluor® 488 Flow Cytometry Assay Kit was used. 
1) 3X105 cells were split into one well of 6 wells plates, which were maintained in 
corresponding medium for 24 h. 
2) 10 μM/ml EdU was added to each well and mixed with the medium.  
3) The 6 wells plates were incubated at 37°C, 5% CO2 for 1 h. 
4) The cells in each well were collected according to the standard protocol for harvesting 
adherent cells.  
5) Harvested cells were kept in FACS tubes and washed once with 2 ml of FACS buffer. 
6) 100 μl of fixative solution (Click-iT® component D) was added to each FACS tube and 
mixed well with the cells.  
7) The FACS tubes were incubated at room temperature for 15 min. 
8) 3 ml of 1% BSA in PBS was added to each FACS tube and mixed well with the cells. 
9) The supernatant was discarded after centrifugation at 1,200 rpm for 8 min. 
10) 100 µl of saponin-based permeabilization and wash reagent (Click-iT® component E) 
was added to each FACS tube. 
11) The FACS tubes were vortexed gently and incubated at room temperature for 15 min. 
12) 500 µl of Click-iT® reaction cocktail was added to each FACS tube, which was mixed 
and incubated at room temperature for 30 min in darkness. 
13) The cells in each FACS tube were washed once by adding 3 ml of saponin-based 
permeabilization and wash reagent. 
14)  The supernatant was discarded after centrifugation at 1,200 rpm for 8 min. 
15) 200 µl of saponin-based permeabilization and wash reagent was added to re-suspend the 
cell pellet. 
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16) Cells were analyzed on a BD FACS Canto II. 488 nm excitation with a green emission 
filter. 
2.10 Statistical analysis  
When samples are normalized distributed, unpaired t-test was used to compare the 
difference of mean values in two independent groups, and data are presented as mean ± SD. 
When samples are not normalized distributed, nonparametric Mann-Whitney U-test was 
used to compare the difference of median values in two independent groups, and data are 
presented as median. 
Statistical analysis was performed with the GraphPad Prism 6.05 version (GraphPad 
Software, Inc., CA 92037 USA). The statistical difference was indicated as * (P<0.05), ** 
(P<0.01), *** (P<0.001) and **** (P<0.0001). 
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3 Results 
3.1 Comparison of tumor growth in stabilin-1 ko mice after injection of 
TS/A-EV and TS/A-SI-CLP cells 
Elevated circulating levels of prototype chitinase-like protein YKL-40 were identified in 
patients with various types of solid cancer and are predictive for bad clinical outcome
127
. 
YKL-40 was found to support tumor growth and metastasis in the mouse model for breast 
cancer
128
. SI-CLP, discovered in our laboratory as a ligand for stabilin-1, is a close structural 
homologue of YKL-40, however the role of SI-CLP in cancer progression remains to be 
unknown. First animal model to investigate the role of SI-CLP in breast cancer progression 
was established in our laboratory (Nan Wang, PhD thesis 2014), and the model was also used 
in current study. In the model TS/A cells were stably transfected with plasmid expressing full 
length SI-CLP and control plasmid empty vector (EV), singe cell derived clones were 
generated and used for the subcutaneous injection into BALB/c mice. This breast carcinoma 
mouse model was most suitable for investigating the effect of SI-CLP on tumor growth since 
no endogenous SI-CLP was detected in TS/A-EV cells and TS/A-EV tumor tissue (Figure 
6A). Previous data obtained by PhD student Nan Wang suggested that SI-CLP suppresses 
tumor growth in this model, possibly by decreasing the amount of stabilin-1+ TAM (Nan 
Wang, PhD thesis, 2014). Knockout of the stabilin-1 gene in BALB/c and C57BL/6 mice 
significantly inhibited tumor growth and metastasis in a TS/A breast carcinoma model and a 
B16 melanoma model
68,129
. However, the role of stabilin-1 in SI-CLP mediated suppression of 
tumor growth was not investigated. Tumor challenge studies were performed in BALB/c 
stabilin-1 ko mice. 
First question that was asked in the present study is whether SI-CLP can also suppress 
tumor growth in the stabilin-1 ko mice, similarly to wt mice. 2.5X10
6
 TS/A-SI-CLP (clone 
CL-P1D5) or TS/A-EV (clone CL-A1) cells were injected subcutaneously into BALB/c wild 
type (wt) or stabilin-1 ko mice. Tumor volume at multiple time points (day 7, 10, 14, 18 and 
21 post-injection) was measured according to the formula described in the Section 2.4. Mice 
were killed on day 21 post-injection and tumor was excised and weighed. Three independent 
tumor injection experiments were performed. In total, sixteen wt mice injected with TS/A-EV 
cells, seventeen wt mice injected with TS/A-SI-CLP cells, fifteen ko mice injected with 
TS/A-EV cells and fourteen ko mice injected with TS/A-SI-CLP cells were included in the 
final statistical analysis. SI-CLP expression levels in BALB/c wt and stabilin-1 ko mice 
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injected by TS/A-SI-CLP cells were found to be comparable (Figure 6B). At all time-points 
analysed, the tumor volume in mice injected with TS/A-SI-CLP cells was significantly 
decreased compared to mice injected with TS/A-EV cells (Figure 7). The tumor volume in 
BALB/c wt mice injected with TS/A-EV cells was 1.51 times bigger than mice injected with 
TS/A-SI-CLP cells on day 7 (Figure 7A), 1.71 times on day 10 (Figure 7B), 2.04 times on day 
14 (Figure 7C), 1.82 times on day 18 (Figure 7D) and 1.4 times on day 21 post-injection 
(Figure 7E). In stabilin-1 ko mice, the tumor volume generated by injecting TS/A-EV cells 
was 2.33 times bigger than those generated by injecting TS/A-SI-CLP cells on day 7 (Figure 
7A), 2.34 times on day 10 (Figure 7B), 2 times on day 14 (Figure 7C), 2 times on day 18 
(Figure 7D), and 2.24 times on day 21 (Figure 7E). The tumor weight in wt mice injected with 
TS/A-EV cells was 1.47 times heavier than the mice injected with TS/A-SI-CLP cells, while 
the tumor weight in ko mice injected with TS/A-EV cells was 2.4 times heavier than those 
injected with TS/A-SI-CLP cells (Figure 7F). The suppression of tumor growth induced by 
SI-CLP was more pronounced in stabilin-1 ko mice compared to BALB/c wt mice. Moreover, 
the tumor volume generated by injecting TS/A-SI-CLP clone in stabilin-1 ko mice was 
smaller than that generated by injecting the same TS/A-SI-CLP clone in BALB/c wt mice at 
all time points analysed, but the distinction reached significance only on day 18 and day 21 
post-injection.  
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Figure 6. Quantitative analysis of SI-CLP expression in tumors generated by subcutaneous 
injection of TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) SI-CLP expression was 
visualized using rat anti-SI-CLP antibody (1B8), scale bar: 100 µm. (B) Quantitative analysis of SI-
CLP positivity in BALB/c wt and stabilin-1 ko mice injected with TS/A-SI-CLP cells (clone P1D5). 
The Mann-Whitney test was used to compare the median of SI-CLP positivity, and NS indicates no 
statistical significance. 
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Figure 7. Comparison of tumor growth of TS/A-EV and TS/A-SI-CLP derived tumors in 
BALB/c wt and stabilin-1 ko mice. (A) Tumor volume on day 7 post-injection. (B) Tumor volume 
on day 10 post-injection. (C) Tumor volume on day 14 post-injection. (D) Tumor volume on day 18 
post-injection. (E) Tumor volume on day 21 post-injection. (F) Tumor weight on day 21 post-injection. 
An unpaired t-test was used to compare the significance of the difference between two groups, and 
data are presented as the mean ± SD. 
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3.2 Comparison of proliferation and migration of TS/A-EV and TS/A-SI-
CLP cells 
Since significant reduction of tumor growth was found in mice injected with TS/A-SI-
CLP cells, it was hypothesized that this effect could be due to the differences in the 
proliferation or migration ability of transfected TS/A cells. The proliferation assay was 
performed on five TS/A-EV clones (CL-1, CL-A1, CL-A3, CL-A4 and CL-A6) and five 
TS/A-SI-CLP clones (CL-P1C8, CL-P1D5, CL-P1F10, CL-P2B7 and CL-P2G7). At least two 
independent experiments were performed for each clone and each experiment was done in 
triplicates. TS/A-EV and TS/A-SI-CLP cells were maintained in RPMI complete medium 
until the cell confluence reached 80%. 10 μM/ml EdU (5-ethynyl-2´-deoxyuridine) was added 
to the medium and incubated with cells at 37°C for 1 h. Alexa Fluor 488 conjugated azide dye 
was used to stain and quantify proliferating cells. All cells excluding cell debris were gated 
for proliferation analysis (Figure 8A). Around 39.4% of TS/A-EV cells (Figure 8B) and 50% 
of TS/A-SI-CLP cells (Figure 8C) were in proliferating status when they were harvested. The 
proliferation ability of TS/A-SI-CLP cells was slightly increased in comparison to TS/A-EV 
cells, but the difference did not reach statistical significance (Figure 8D, P=0.0952).  
The ability of tumor cells to spread and migrate is vital for tumor progression
130
. The 
migration assay was performed using four TS/A-EV clones (CL-A1, A3, A4, A6) and four 
TS/A-SI-CLP clones (P1D5, P1C8, P1F10, P2B7). Two independent experiments were 
carried out for each clone, and each migration experiment was performed in triplicates. 
Migration of TS/A-EV and TS/A-SI-CLP cells was first tested with a 5 µm pore 
polycarbonate membrane insert, but no cells could pass through the membrane. The mean 
nuclear size of TS/A-EV and TS/A-SI-CLP cells is around 10 µm, so Transwell with a pore 
size of 8 μm was chosen. A concentration gradient of 2% to 20% FCS was used to recruit 
FOXQ1 transfected mouse macrophage-like RAW 264.7 cells in our lab (IIya Ovsiy, PhD 
thesis, 2013), so the concentration gradient of FCS was used to assess the migration ability of 
SI-CLP transfected TS/A cells. 5X10
5 
TS/A-EV and TS/A-SI-CLP cells maintained in RPMI 
+ 2% FCS medium were seeded in the top chamber, and the lower chamber was filled with 
RPMI + 20% FCS medium. The migration assay was performed in a 37°C incubator for 16 h. 
Migrated cells adhered on the lower side of the membrane and were visualized with DAPI 
staining (Figure 9A). Migrated cells were photographed under a fluorescence microscope 
equipped with a 32x objective and the migrated cells in 10 random images were counted to 
get the mean values for each clone. The chemotactic index was calculated according to the 
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following formula: number of migrated cells in experimental group/ the lowest number of 
migrated cells in control well
131
. More TS/A-SI-CLP cells were found in the lower side of 
membrane in comparison to TS/A-EV cells, but the difference did not reach statistically 
significant (Figure 9B, P=0.3429). 
 
Figure 8. Comparison of the proliferation of TS/A-EV and TS/A-SI-CLP cells. (A) The SSC-A 
and FSC-A were adjusted to select the correct cell population for analysis. Cell debris was excluded 
(bottom, left hand corner). (B) Representative histogram demonstrating percentage of proliferating 
TS/A-EV cells. (C) Representative histogram demonstrating percentage of proliferating TS/A-SI-CLP 
cells. (D) Comparison of proliferation of TS/A-EV and TS/A-SI-CLP cells. The Mann-Whitney Test 
was used to compare the significance of difference, and data are presented as the median. NS indicates 
no statistical significance.  
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Figure 9. Comparison of the migration of TS/A-EV and TS/A-SI-CLP cells. (A) Representative 
picture of migrated TS/A-EV and TS/A-SI-CLP cells on the lower side of the membrane was 
visualized by DAPI staining, scale bar: 100 µm. (B) Comparison of the chemotactic index of migrated 
TS/A-EV and TS/A-SI-CLP cells. The Mann-Whitney Test was used to compare the significance of 
difference, and data are presented as the median. NS indicates no statistical significance. 
 
3.3 Comparison of angiogenesis in TS/A-EV and TS/A-SI-CLP tumors 
Tumor neovascularization is important for local tumor growth, and YKL-40-mediated 
support of tumor growth was found to be associated with its pro-angiogenesis activities
9,39,56
. 
Over-expression of YKL-40 in HCT-116 and MDA-MB-231 cells promoted angiogenesis 
(evaluated by the levels of CD31+ expression) in mouse models for breast adenocarcinoma 
and colorectal carcinoma
9
. Thus, it was examined whether SI-CLP affected tumor 
neovascularization in TS/A tumors. TS/A tumors were found to be highly vascularized and 
tumor vessels were visualized using antibodies against CD31 protein, the major markers of 
vascular endothelium. In TS/A tumor tissue, CD31 was found on vessel-like structures and 
single cells (Figure 10A). The vascularization in BALB/c wt mice was investigated in six 
TS/A-EV and ten TS/A-SI-CLP tumors, and was found to be unaltered (Figure 10B). In 
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stabilin-1 ko mice, the expression of CD31 protein was investigated in seven TS/A-SI-CLP 
tumors and five TS/A-EV tumors from three experiments. CD31 positivity was not affected 
by SI-CLP in the absence of stabilin-1 expression. 
   
Figure 10. Quantitative analysis of CD31 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) CD31 
expression was visualized using rat anti-mouse CD31 antibody, scale bar: 100 µm. (B) Comparison of 
the positivity of CD31 protein in BALB/c wt and stabilin-1 ko mice injected with TS/A-EV or TS/A-
SI-CLP cells. The Mann-Whitney test was used to compare the significance of difference between two 
groups, and data are presented as the median. NS indicates no statistical significance. 
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3.4 Comparison of TAM infiltration in TS/A-EV and TS/A-SI-CLP tumors 
Even though TS/A-SI-CLP cells demonstrated slightly enhanced proliferation (25%) and 
migration ability (31%) in comparison with TS/A-EV cells, the injection of TS/A-SI-CLP 
cells in both BALB/c wt and stabilin-1 ko mice resulted in attenuated tumor growth in vivo. It 
was hypothesized that the inhibition of tumor growth could be a result of changes in tumor 
stroma composition, but not in tumor cells. TAM are important components of tumor stromal 
cells, which affect tumor progression in multiple ways
86
. Since TAM were reported to 
promote tumor progression of human breast cancer
82
, the infiltration and phenotype of TAM 
in the TS/A tumor model was also investigated. CD68 was previously used as a pan-
macrophage marker in a mouse TS/A mammary tumor model
68
, so the positivity of CD68 
staining imply the total amount of TAM. Tumors generated by injecting TS/A-EV and TS/A-
SI-CLP cells into BALB/c wt and stabilin-1 ko mice were abundantly infiltrated by TAM 
(Figure 11A).  
The positivity of CD68 protein was investigated in ten TS/A-EV tumors and eight TS/A-
SI-CLP tumors generated in BALB/c wt mice from three independent tumor injection 
experiments. For each mouse, three consecutive sections were stained and quantified. In 
BALB/c wt mice, the positivity of CD68 in TS/A-EV tumors was 2.5 times higher than in 
TS/A-SI-CLP tumors (Figure 11B). In stabilin-1 ko mice, eight TS/A-EV tumors and eight 
TS/A-SI-CLP tumors were used to quantify the positivity of CD68 expression. Tumors 
generated by injecting TS/A-EV cells into stabilin-1 ko mice demonstrated a 1.84 times 
higher CD68 expression than tumors generated by injecting TS/A-SI-CLP cells into stabilin-1 
ko mice (Figure 11B). There was no statistical difference between CD68 positivity in BALB/c 
wt and stabilin-1 ko mice injected with TS/A-SI-CLP cells, suggesting that the presence of 
stabilin-1 does not alter SI-CLP induced changes in TAM infiltration. 
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Figure 11. Quantitative analysis of CD68 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) CD68 
was visualised using rat anti-mouse CD68 antibody, scale bar: 100 µm. (B) Comparison of the 
positivity of CD68 protein in BALB/c wt and stabilin-1 ko mice injected with TS/A-EV or TS/A-SI-
CLP cells. The Mann-Whitney test was used to compare the significance of difference between two 
groups, and data are presented as the median. 
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3.5 Comparison of other TAM markers in TS/A-EV and TS/A-SI-CLP 
tumors  
Next, the expression of several polarization and activation markers of infiltrating TAM 
was analyzed in TS/A-SI-CLP and TS/A-EV tumors. CD206 is one of major markers for 
alternative activation of macrophages, and CD206 positive TAM are found to be 
proangiogenic
132
. CD206 was abundantly found in TS/A-EV and TS/A-SI-CLP tumor tissues 
(Figure 12A). The expression of CD206 protein in BALB/c wt mice was investigated in ten 
TS/A-EV and twelve TS/A-SI-CLP tumors obtained from three independent experiments. In 
BALB/c wt mice, the expression of CD206 protein in TS/A-EV tumors was 2.26 times higher 
than TS/A-SI-CLP tumors (Figure 12B). In stabilin-1 ko mice, CD206 expression was 
investigated in nine TS/A-EV and six TS/A-SI-CLP tumors. Tumors generated by injecting 
TS/A-EV cells into stabilin-1 ko mice demonstrated 1.68 times higher CD206 expression than 
tumors generated by injecting TS/A-SI-CLP cells (Figure 12B).  
Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) was initially used as a 
marker of lymphatic endothelial cells, but its expression was also found in a subset of TAM in 
murine models of TS/A mammary carcinoma (Alexandru Gudima, Master thesis, 2013) and 
B16F1 melanoma tissues
133
. In TS/A tumors, LYVE-1 protein was rarely found in typical 
lymph vessel like structures, and was preferentially expressed by single cells that can be 
identified as macrophages by morphology (Figure 13A). The expression of LYVE-1 protein 
was investigated in eight wt mice injected with TS/A-EV cells and nine wt mice injected with 
TS/A-SI-CLP cells from three experiments. In BALB/c wt mice, the positivity of LYVE-1 
protein in TS/A-EV tumors was 4 times higher than TS/A-SI-CLP cell tumors (Figure 13B). 
In stabilin-1 ko mice, LYVE-1 expression was investigated in six TS/A-EV and five TS/A-SI-
CLP tumors. In stabilin-1 ko mice, tumors generated by injecting TS/A-EV cells 
demonstrated a 4.23 times higher LYVE-1 expression than tumors generated by injecting 
TS/A-SI-CLP cells (Figure 13B). Moreover, the difference of LYVE-1 expression between 
TS/A-EV and TS/A-SI-CLP tumors in both BALB/c wt and stabilin-1 ko mice was more 
pronounced compared to CD68 and CD206 markers. 
Stabilin-1 is a multifunctional scavenger receptor expressed by TAM and demonstrates 
tumor-promoting effect in mouse mammary carcinoma and melanoma models
68,129
. The 
expression of stabilin-1 was compared in twelve BALB/c wt mice injected with TS/A-EV 
cells and fourteen BALB/c wt mice injected with TS/A-SI-CLP cells from three independent 
experiments. Stabilin-1 positive cells were abundant found in TS/A-EV and TS/A-SI-CLP 
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tumors (Figure 14A). Moreover, the positivity of stabilin-1 expression in TS/A-EV tumors 
was 2.18 times higher than that detected in TS/A-SI-CLP tumors (Figure 14B). As expected, 
stabilin-1 protein was not detectable in stabilin-1 ko mice (Figure 14A, lower panel). 
   
Figure 12. Quantitative analysis of CD206 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) CD206 
was visualised using rat anti-mouse CD206 antibody, scale bar: 100 µm. (B) Comparison of the 
positivity of CD206 protein in BALB/c wt and stabilin-1 ko mice injected with TS/A-EV or TS/A-SI-
CLP cells. The Mann-Whitney test was used to compare the significance of difference between two 
groups, and data are presented as the median. 
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Figure 13. Quantitative analysis of LYVE-1 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) LYVE-
1 was visualised using biotin conjugated rabbit anti-mouse LYVE-1 antibody, scale bar: 100 µm. (B) 
Comparison of the positivity of LYVE-1 protein in BALB/c wt and stabilin-1 ko mice injected with 
TS/A-EV or TS/A-SI-CLP cells. The Mann-Whitney test was used to compare the significance of 
difference between two groups, and data are presented as the median. 
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Figure 14. Quantitative analysis of stabilin-1 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) Stabilin-
1 was visualised using rabbit anti-stabilin-1 antibody (RS1), scale bar: 100 µm. (B) Comparison of the 
positivity of stabilin-1 protein in BALB/c wt mice injected with TS/A-EV or TS/A-SI-CLP cells. An 
unpaired t-test was used to compare the significance of difference, and data are presented as the mean 
± SD. 
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3.6 Comparison of the expression of T cell markers in TS/A-EV and TS/A-
SI-CLP tumors 
T cells are important regulators of intratumoral immune reactions including tumor 
rejection and tumor tolerance. The infiltration of T cells in TS/A tumor models was 
investigated using antibody against CD3, a commonly used marker of T cells. In BALB/c wt 
mice, CD3 expression was investigated in twelve TS/A-EV tumors and thirteen TS/A-SI-CLP 
tumors from three independent experiments. CD3 positive cells were broadly found in TS/A-
EV tumors, while much less CD3 positive cells were detected in TS/A-SI-CLP tumors (Figure 
15A). In BALB/c wt mice the positivity of CD3 in TS/A-EV tumors was 2.74 times higher 
than that in TS/A-EV tumors (Figure 15B, P=0.0024), indicating reduced infiltration of T 
cells into TS/A-SI-CLP tumors. In stabilin-1 ko mice, CD3 expression was investigated in ten 
TS/A-EV and eight TS/A-SI-CLP tumors. Tumors generated by injecting TS/A-EV cells into 
stabilin-1 ko mice demonstrated 6 times higher CD3 expression than tumors generated by 
injecting TS/A-SI-CLP cells into stabilin-1 ko mice (Figure 15B). Moreover, CD3 positivity 
in BALB/c wt mice injected with TS/A-SI-CLP cells was significantly higher than that in 
stabilin-1 ko mice injected with TS/A-SI-CLP cells, which suggested the reduction of CD3 
positive cells in TS/A-SI-CLP tumors was affected by the absence of stabilin-1 (P=0.0137).  
Increased infiltration of CD8 positive T cells in human breast cancer tissue reduces the 
risk of death
134
. Therefore, we analyzed whether the presence of SI-CLP affects the amount of 
CD8 positive T cells in the tumor mass. CD8 expression in BALB/c wt mice was assessed in 
eight TS/A-EV tumors and eleven TS/A-SI-CLP tumors from three experiments. In stabilin-1 
ko mice, the expression of CD8 protein was investigated in ten TS/A-EV tumors and five 
TS/A-SI-CLP tumors. In BALB/c wt mice, there was a tendency for reduced levels of CD8 in 
TS/A-SI-CLP tumors, while in stabilin-1 ko mice more CD8+ T cells were found in TS/A-SI-
CLP tumors. Minor CD8 positive cells were found in TS/A-SI-CLP and TS/A-EV tumors 
(Figure 16A), while the amounts of CD8 positive T cells was not affected by SI-CLP presence 
(Figure 16B). 
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Figure 15. Quantitative analysis of CD3 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) CD3 
expression was visualized using rat anti-mouse CD3 antibody, scale bar: 100 µm. Red arrows indicate 
CD3 positive cell. (B) Comparison of the positivity of CD3 protein in BALB/c wt and stabilin-1 ko 
mice injected with TS/A-EV or TS/A-SI-CLP cells. The Mann-Whitney test was used to compare the 
significance of difference between two groups, and data are presented as the median. 
 
Results 
 71 
 
Figure 16. Quantitative analysis of CD8 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) CD8 
expression was visualized using rat anti-mouse CD8 antibody, scale bar: 100 µm. (B) Comparison of 
the positivity of CD8 protein in BALB/c wt and stabilin-1 ko mice injected with TS/A-EV or TS/A-SI-
CLP cells. The Mann-Whitney test was used to compare the significance of difference between two 
groups, and data are presented as the median. NS indicates no statistical significance. 
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Next, the expression of CD4 (marker of helper T cells) was analyzed. CD4 positive 
helper T cells suppress tumor immunity by enhancing the function of regulatory T cells
135
. In 
BALB/c wt mice, the expression of CD4 protein was investigated in twelve TS/A-SI-CLP 
tumors and ten TS/A-EV tumors from three experiments. In stabili-1 ko mice, the expression 
of CD4 protein was investigated in nine TS/A-SI-CLP tumors and eight TS/A-EV tumors 
from three experiments. CD4 expression in TS/A-EV tumors was strong while only single 
CD4 positive cells were found in TS/A-SI-CLP tumors (Figure 17A). The difference of CD4 
expression between TS/A-EV and TS/A-SI-CLP tumors reached 2.25 times in BALB/c wt 
mice, while the reduction of CD4 expression in TS/A-SI-CLP tumors was 1.9 times in 
stabilin-1 ko mice (Figure 17B).  
A subpopulation of CD4 positive T cells in tumors is known to express transcription 
factor FoxP3 which specifically marks regulatory T cells (Treg), known to suppress anti-
tumor immunity in breast cancer
136
. The expression of FoxP3 protein in BALB/c wt mice was 
investigated in seven TS/A-EV tumors and nine TS/A-SI-CLP tumors from three experiments. 
In stabilin-1 ko mice, FoxP3 expression was investigated in seven TS/A-EV tumors and four 
TS/A-SI-CLP tumors from three experiments. Positive FoxP3 staining was visualized as a red 
dot in the nuclear area of cells (Figure 18A), and 10 images were taken for each tumor tissue 
stained with FoxP3 protein under light microscope equipped with a 20x objective. FoxP3 
positive cells were counted with ImageJ software, and the mean positive cells were calculated 
by averaging all FoxP3 positive cells in ten images. In BALB/c wt mice FoxP3 positive Treg 
cells detected in TS/A-EV tumors were 2.55 times higher than that in TS/A-SI-CLP tumors, 
while in stabilin-1 ko mice the reduction of FoxP3 positive Treg cells was not significant 
(Figure 18B, P=0.2939).  
PD-1 is a type I membrane receptor specifically expressed by T cells and pro-B cells. 
The binding of PD-1 with its specific ligands PD-L1 and PD-L2 leads to the apoptosis or 
deactivation of effector T cells
137
. The application of anti-PD-1 monoclonal antibody in 
human melanoma patients enhanced the effectiveness of specific T cells killing and prolonged 
overall survival
138
. The application of anti-PD-1 single agent in patients with advanced triple 
negative breast cancer was also reported, but the clinical trial results still have to be 
obtained
139
. In BALB/c wt mice, the expression of PD-1 protein was investigated in seven 
TS/A-EV tumors and five TS/A-SI-CLP tumors from three experiments. In stabilin-1 ko mice, 
PD-1 expression was investigated in six TS/A-SI-CLP tumors and five TS/A-EV tumors from 
three experiments. In BALB/c wt mice, PD-1 positivity in TS/A-EV tumors was 2.2 times 
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higher than in TS/A-SI-CLP tumors, while the reduction on PD-1 in TS/A-SI-CLP tumors 
reached 3.8 times in stabilin-1 ko mice (Figure 19).  
 
Figure 17. Quantitative analysis of CD4 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) CD4 
expression was visualized using biotin conjugated rat anti-mouse CD4, scale bar: 100 µm. (B) 
Comparison of the positivity of CD4 protein in BALB/c wt and stabilin-1 ko mice injected with TS/A-
EV or TS/A-SI-CLP cells. The Mann-Whitney test was used to compare the significance of difference 
between two groups, and data are presented as the median. 
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Figure 18. Quantitative analysis of FoxP3 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) FoxP3 
expression was visualized using biotin conjugated rat anti-mouse FoxP3, scale bar: 100 µm. Red 
arrows indicate FoxP3 positive cell. (B) Comparison of the amount of FoxP3 positive cells in BALB/c 
wt and stabilin-1 ko mice injected with TS/A-EV or TS/A-SI-CLP cells. The Mann-Whitney test was 
used to compare the significance of difference between two groups, and data are presented as the 
median. NS indicates no statistical significance. 
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Figure 19. Quantitative analysis of PD-1 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) PD-1 
expression was visualized using goat anti-mouse PD-1 antibody, scale bar: 100 µm. (B) Comparison 
of the positivity of PD-1 protein in BALB/c wt and stabilin-1 ko mice injected with TS/A-EV or 
TS/A-SI-CLP cells. The Mann-Whitney test was used to compare the significance of difference 
between two groups, and data are presented as the median. NS indicates no statistical significance. 
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3.7 Comparison of other infiltrating immune cells in TS/A-EV and TS/A-
SI-CLP tumors 
Eosinophils are considered as bystander cells in anti-tumor immunity, but their role in 
tumor rejection through recruitment of CD8+ T cells has recently been revealed
140
. YM1, one 
of the chitinase-like proteins, exerts eosinophil chemotactic activity in vivo and in vitro. Thus, 
it was examined whether SI-CLP expression affected eosinophil infiltration in TS/A-SI-CLP 
tumors raised in BALB/c wt and stabilin-1 ko mice. Eosinophils were specifically detected 
using antibodies against Siglec-F protein, and most of eosinophils were localized on the 
periphery of the tumor mass (Figure 20A). In BALB/c wt mice, the expression of Siglec-F 
protein was investigated in eleven TS/A-EV tumors and nine TS/A-SI-CLP tumors from three 
experiments. In stabilin-1 ko mice, Siglec-F expression was investigated in eight TS/A-EV 
tumors and six TS/A-SI-CLP tumors from three experiments. The expression of the Siglec-F 
protein in TS/A-EV and TS/A-SI-CLP tumors was not significantly changed, which indicates 
that the infiltration of eosinophils was not affected by SI-CLP directly (Figure 20B).  
The role of neutrophils in tumor progression is controversial
141
. An increased number of 
neutrophils in breast cancer was reported to facilitate tumor metastasis
142
, while in another 
murine model using 4T1 cells more neutrophils in the orthotopic engrafted tumor inhibited 
the primary tumor growth and lung metastasis
143
. Neutrophils were detected using antibodies 
against Gr-1 protein, which was abundantly found in TS/A tumor tissue (Figure 21A). In 
BALB/c wt mice the amounts of neutrophils were compared in seven TS/A-EV tumors and 
eight TS/A-SI-CLP tumors, and it was found to be unaltered (Figure 21B). In stabilin-1 ko 
mice, the amount of neutrophils was investigated in six TS/A-EV tumors and four TS/A-SI-
CLP tumors. Similarly, there was no significant difference in neutrophil infiltration (Figure 
21B).  
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Figure 20. Quantitative analysis of Siglec-F expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) Siglec-F 
expression was visualized using rat anti-mouse Siglec-F, scale bar: 100 µm. (B) Comparison of the 
positivity of Siglec-F protein in BALB/c wt and stabilin-1 ko mice injected with TS/A-EV or TS/A-
SI-CLP cells. The Mann-Whitney test was used to compare the significance of difference between two 
groups, and data are presented as the median. NS indicates no statistical significance. 
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Figure 21. Quantitative analysis of Gr-1 expression in tumors generated by subcutaneous 
injection of TS/A-EV and TS/A-SI-CLP cells into BALB/c wt and stabilin-1 ko mice. (A) Gr-1 
expression was visualized using rat anti-mouse Ly6G antibody, scale bar: 100 µm. (B) Comparison of 
the positivity of Gr-1 protein in BALB/c wt and stabilin-1 ko mice injected with TS/A-EV or TS/A-SI-
CLP cells. The Mann-Whitney test was used to compare the significance of difference between two 
groups, and data are presented as the median. NS indicates no statistical significance. 
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3.8 SI-CLP inhibits chemotaxis of murine bone marrow derived 
macrophages 
Since the infiltration of macrophages was inhibited in TS/A-SI-CLP tumors, it was 
hypothesized that SI-CLP may directly affect macrophage chemotaxis. To test this hypothesis, 
mouse bone marrow cells were isolated from BALB/c mice and differentiated into 
macrophages in DMEM medium supplemented with M-CSF for four days. Next, 100 ng/ml 
of purified murine SI-CLP protein from HEK-293 cells (CUSABIO, China) was incubated 
with murine bone marrow derived macrophages (BMDM) for 30 min followed by assessment 
of chemotaxis in response to 100 ng/ml of murine CCL2 protein for 3 h. Each experiment was 
performed in triplicates, and three mice were used in three independent experiments. 10 
random images were taken for each Transwell under fluorescence microscope equipped with 
a 32x objective, and migrated cells on the lower side of membrane were visualized by DAPI 
staining. The chemotaxis of BMDM was inhibited after incubation with 100 ng/ml of purified 
SI-CLP protein for 30 min (Figure 22).  
Next, the specific effect of SI-CLP on macrophage migration was confirmed using 
mouse SI-CLP containing supernatants derived from alphavirus infected BHK-21 cells 
(provided by Dr. Anna Zajakina, Department of Protein Engineering, Biomedical Research 
and Study center, Riga, Latvia). SI-CLP containing supernatant (2,5 µl, 5µl, 10 µl and 20µl) 
from BHK-21 recSFV1/murine SI-CLP cells or control (SI-CLP negative) supernatant of 
recSFV1/Luc transfected cells were added to 1X10
6 
BMDM suspended in 1 ml of DMEM 
medium. After 16 hours of incubation at 37°C, BMDM were harvested and diluted in DMEM 
medium at 5X10
6
/ml. 5X10
5
 BMDM in 100 µl of DMEM medium was seeded in the top well 
and murine CCL2 was added to the lower chamber as a chemotactic factor. The migration 
assay was performed in response to CCL2 for 3 h. The migration of BMDM was significantly 
inhibited after pre-incubation with SI-CLP containing supernatant for all amounts of 
supernatants used (Figure 23A).  Further, to demonstrate the specific effect of SI-CLP on 
BMDM migration, SI-CLP protein was depleted from supernatants by immunoprecipitation 
using rat anti-SI-CLP antibody 1B8 immobilized on the protein G beads. Empty protein G 
bead and beads with immobilized rat IgG were used as a control (Figure 23B). Intact SI-CLP 
containing supernatant and SI-CLP depleted supernatant from BHK-21 recSFV1/ murine SI-
CLP were added to 1X10
6
 BMDM. BMDM were harvested 16 h later and used for the 
chemotaxis assay. The results showed that the depletion of SI-CLP from BHK-21 recSFV1/ 
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murine SI-CLP supernatant abrogated the inhibitory effect of BHK-21 recSFV1/ murine SI-
CLP supernatant on chemotaxis of BMDM (Figure 23C). 
 
Figure 22. The effect of SI-CLP on the chemotaxis of murine BMDM. (A) Migrated cells on the 
lower side of membrane were fixed and visualized by DAPI staining, scale bar: 100 µm. (B) 
Comparison of chemotactic index in BMDM treated with or without SI-CLP protein. An unpaired t-
test was used to compare the significance of difference, and data are presented as mean, n=3.  
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Figure 23. The effect of SI-CLP containing supernatant on chemotaxis of murine BMDM. (A) 
Comparison of the chemotactic index of BMDMs incubated with BHK-21 recSFV/Luc or BHK-21 
recSFV/SI-CLP conditioned supernatant. (B) Western blot image demonstrating depletion of SI-CLP 
from BHK-21 recSFV/SI-CLP conditioned supernatant after Protein G Sepharose beads conjugated 
with anti-SI-CLP antibody were added. Protein G Sepharose beads and Protein G Sepharose beads 
conjugated with rat IgG antibody were used as control. (C) The chemotaxis of murine BMDM after 
incubation with intact and SI-CLP depleted supernatant of BHK-21 recSFV/SI-CLP. An unpaired t-
test was used to compare the significance of difference, and data are presented as the mean ± SD.  
Results 
 82 
Thus, mouse SI-CLP (both commercial recombinant purified as well as alphavirus-
derived) demonstrated a clear inhibitory effect on the CCL2-induced chemotaxis of murine 
BMDM. Therefore, the next question was to analyze whether SI-CLP has inhibitory effect on 
human monocytes. Freshly isolated CD14+ human monocytes were incubated with 100 ng/ml 
of recombinant purified human SI-CLP protein produced in HEK-293 cells (CUSABIO, 
China). Incubation was performed in macrophage SFM medium for 16 h at 37°C. After 
incubation with SI-CLP, monocytes were harvested and re-suspended in SFM medium at 
5X10
6
/ml. Monocytes (100 µl, total amount of 5X10
5
 cells) were placed on the top well of a 5 
μm Transwell, and the chemotaxis assay was performed in response to 100 ng/ml human 
CCL2 protein added to the lower chamber for 3 h. The chemotaxis assay for monocytes 
derived from each individual donor was performed in triplicates, and five independent donors 
were used in the assay. Migrated monocytes were found on the lower side of the membrane 
and in the lower chamber. The representative images of migrated monocytes on the 
membrane with or without SI-CLP incubation are shown on Figure 24A. Inhibited chemotaxis 
of human CD14+ monocytes in response to CCL2 was observed in four of five individual 
donors (BC906-03, BC910-03, BC915-01 and BC915-02) and chemotaxis of the donor 
BC915-03 was not affected by SI-CLP (Figure 24B). The level of SI-CLP mediated inhibition 
of monocytes migration was individual for monocyte isolated from individual donors, which 
is consistence with the study demonstrating donors-specific monocyte reactions to the 
spectrum of stimuli
144
. The strongest effect was observed for the BC 910-03 (Figure 24).  
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Figure 24. Effect of SI-CLP on the chemotaxis of human peripheral blood derived CD14+ 
monocytes. (A) Representative pictures of migrated CD14+ human monocytes on the lower side of 
membrane with or without SI-CLP incubation, scale bar: 100 µm. (B) Comparison of the chemotactic 
index of CD14+ human monocytes with or without SI-CLP protein incubation on the membrane (left 
panel) and in the lower chamber (right panel). Unique code number of individual donors is indicated, 
and the mean chemotactic index of each donor are presented.  
 
3.9 SI-CLP does not affect the chemotaxis of naive T cells 
Since the total amount of CD3 positive cells in TS/A-SI-CLP tumors was decreased 
compared to that in TS/A-EV tumors, we investigated whether SI-CLP directly affected the 
chemotaxis of T cells. Naive T cells were isolated from spleen tissue of BALB/c wt mice, and 
the purity of T cells used in the chemotaxis assay was over 95%. The SSC-A and FSC-A 
parameters were adjusted to gate all live cells (Figure 25A), and the purity of naive T cells 
was analyzed using APC conjugated rat anti-mouse CD3 antibody (Figure 25B). Isolated T 
cells were maintained in RPMI medium for 4 h before performing chemotaxis. 100 ng/ml 
purified murine SI-CLP protein was added to the T cells, which were harvested 30 min later 
for performing chemotaxis in response to purified murine CCL19 protein. 5X10
5
 naive T cells 
in 100 µl of RPMI medium were seeded in the top well of a 5 μm Transwell, and 100 ng/ml 
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of CCL19 were added into the lower chamber as a chemotactic factor. The migration was 
performed at 37°C, in a 5% CO2 incubator for 3 h. The migrated cells in the lower chamber 
were collected and counted by a cell counter (CASY Model TT). No cells were detected on 
the lower side of the membrane. Statistical analysis revealed that SI-CLP did not affect the 
chemotaxis of naive T cells either in steady state conditions or in response to CCL19 (Figure 
25C). Prolonged incubation time with SI-CLP also did not affect the chemotaxis of naive T 
cells (Figure 25D).  
 
Figure 25. The effect of SI-CLP on the chemotaxis of mouse naive T cells. (A) The SSC-A and 
FSC-A parameters were adjusted to select all live cells for analysis. Cell debris was excluded (bottom, 
left hand corner). (B) Purity of isolated T cells was confirmed with APC conjugated rat anti-mouse 
CD3 antibody. The red line represents staining with APC conjugated rat IgG antibody and the blue 
line represents staining with APC conjugated rat anti-mouse CD3 antibody. (C) Comparison of the 
chemotactic index of naive T cells after incubation with SI-CLP for 30 min. (D) Comparison of the 
chemotactic index of naive T cells after incubation with SI-CLP for 16 h. An unpaired t-test was used 
to compare the significance of difference, and data are presented as the mean ± SD. NS indicates no 
statistical significance. 
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3.10 Analysis of specific markers of polarization in TAM isolated from 
TS/A-EV and TS/A-SI-CLP tumors 
Previous data in vivo and in vitro revealed that the chemotaxis of macrophages was 
inhibited by SI-CLP. However, specific markers of macrophage activation/polarization, such 
as CD206, stabilin-1 and LYVE-1, were also suppressed in TS/A-SI-CLP tumors. This 
reduced expression of TAM markers could be a consequence of reduced TAM infiltration in 
TS/A-SI-CLP tumors and did not involve changes in the TAM phenotype. Alternatively, 
reduction in TAM numbers in TS/A-SI-CLP tumors could be accompanied by additional 
phenotypic changes. To confirm this hypothesis, TAM were isolated from TS/A-EV and 
TS/A-SI-CLP tumors raised in wt BALB/c mice and assessed for gene expression using RT-
PCR analysis. 
Four TS/A-SI-CLP (CL-P1D5, P1C8, P1F10 and P2G7) and four TS/A-EV (CL-A1, CL-
A3, CL-A6 and CL1) clones were injected subcutaneously into BALB/c wt mice. For each 
clone, 5 mice were used. The tumor volume and weight on the day of TAM isolation were 
shown in the Figure 26.  
 
 
Figure 26. TAM isolated from tumors generated by subcutaneous injection of TS/A-EV and 
TS/A-SI-CLP cells into BALB/c wt mice. (A) Comparison of tumor volume of TS/A-EV and TS/A-
SI-CLP tumors on day 21 post-injection. (B) Comparison of tumor weight of TS/A-EV and TS/A-SI-
CLP tumors on day 21 post-injection. The Mann-Whitney test was used to compare the significance of 
difference between two groups, and data are presented as the median. 
 
TAM were isolated from tumors generated by injecting TS/A-EV cells and tumors 
generated by injecting TS/A-SI-CLP cells in BALB/c wt mice according to the previously 
published protocol resulting in the 92-95% TAM purity
68
. As an additional control the purity 
of TAM was verified by a-CD68 immunofluorescent analysis and demonstrated that over 96% 
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of TAM were positive for CD68 (Figure 27). Purified TAM were maintained in DMEM 
complete medium and non-adherent cells were washed away after 30 min. Adherent TAM 
were used for the RNA isolation. Tumors derived from following TS/A clones were used for 
TAM isolation: TS/A-EV clones (CL-A1, 4 mice; CL-A3, 3 mice; CL-A6, 3 mice; CL-1, 4 
mice), TS/A-SI-CLP clones (P1D5, 4 mice; P1C8, 5 mice; P1F10, 3 mice; P2G7, 5 mice). 
Pooled RNA samples were generated for each clone and analyzed by RT-PCR for the 
expression of macrophage markers related to their polarization type and involved in tumor 
progression. 
 
 
Figure 27. Confocal microscopy analysis of CD68 expression in TAM isolated from BALB/c wt 
mice injected with TS/A-EV and TS/A-SI-CLP cells. TAM were stained first with rat anti-mouse 
CD68 antibody or rat isotype control IgG2a, followed by Alexa 488 conjugated donkey anti-rat 
secondary antibody (shown in green). Blue color visualizes nuclei stained with DRAQ5. Scale bar is 
25 µm.  
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RT-PCR analysis demonstrated that expression of macrophage activation/polarization 
markers including CD206, LYVE-1, stabilin-1, IL-1 β, IL-6, IL-10, TNF-α, VEGF-A and 
TGF-β are not significantly changed between TAM isolated from TS/A-EV and TS/A-SI-CLP 
tumors (Figure 28). These data suggested that expression of SI-CLP in TS/A tumor model 
does not affect TAM transcriptional profile, related to the type of their polarization and pro-
tumor activities.  
 
Figure 28. RT-PCR analysis of selected gene expression in TAM isolated from TS/A-EV and 
TS/A-SI-CLP tumors using real-time PCR. The Mann-Whitney test was used to compare the 
significance of difference between TAM-EV and TAM-SI-CLP, and data are presented as the median. 
NS indicates no statistical significance. 
 
 
 
 
Results 
 88 
3.11 Functional analysis of TAM isolated from TS/A-EV and TS/A-SI-CLP 
tumors 
TAM are known to support tumor cell proliferation and tumor growth by the secretion of 
growth factors. Next, it was analyzed whether conditioned medium of TAM isolated from 
TS/A-EV and TS/A-SI-CLP tumors can differentially affect proliferation of TS/A cells in 
vitro (Figure 29). To obtain conditioned supernatants, 3X10
6
 purified TAM were cultured in 
DMEM complete medium for 16 h. The TAM-conditioned supernatants were added to 
DMEM complete medium in a ratio of 1:3 to obtain TAM-DMEM medium. TAM-DMEM 
medium was used for the cultivation of TS/A cells for 48 h. TS/A cells were harvested and 
used for the EdU cell proliferation assay. The SSC-A and FSC-A parameters were adjusted to 
gate all alive cells (Figure 29A). About 63% TS/A cells stimulated by the supernatant derived 
from TAM-EV were proliferating (Figure 29B), and 66% TS/A cells stimulated by the 
supernatant derived from TAM-SI-CLP were proliferating (Figure 29C). These results 
demonstrated supernatants of TAM isolated from TS/A-SI-CLP tumors did not alter TS/A cell 
proliferation compared to TAM supernatants derived from vector clones (Figure 29D). These 
data additionally demonstrated that presence of SI-CLP in TS/A model does not affect TAM 
phenotype, and its tumor suppressive effects is related to the significantly decreased 
infiltration of TAM.  
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Figure 29. Flow cytometry analysis of the proliferation of TS/A cells stimulated with TAM-
DMEM medium. (A) The SSC-A and FSC-A parameters were adjusted to exclude cell debris (bottom, 
left hand corner) for flow cytometry analysis. (B) The percentage of proliferating TS/A cells 
stimulated by supernatants of TAM isolated from TS/A-EV tumors. (C) The percentage of 
proliferating TS/A cells stimulated by supernatants of TAM isolated from TS/A-SI-CLP tumors. (D) 
Comparison of the percentage of proliferating TS/A cells stimulated by TAM conditioned medium 
from TS/A-EV and TS/A-SI-CLP tumors. The Mann-Whitney test was used to compare the 
significance of difference between two groups, and data are presented as the median. NS indicates no 
statistical significance. 
Discussion 
 90 
4 Discussion 
4.1 Effect of SI-CLP on tumor growth in stabilin-1 knockout mice. 
Chitinases and chitinase-like proteins implicate in the pathological process in a set of 
human diseases, including cardio-metabolic disorders, allergy, and cancer
1,7
. The best 
investigated chitinase-like protein in tumor progression is YKL-40. High YKL-40 levels in 
the circulation of patients with different types of  cancer are associated with poor prognosis
127
. 
YKL-40 participates in each stage of tumor progression including tumor initiation, cancer cell 
proliferation and migration, as well as tumor angiogenesis
7
. However, the role of other human 
chitinase-like proteins (SI-CLP and YKL-39) in tumor progression remained unclear. First 
animal model for the investigation of the function of SI-CLP on breast adenocarcinoma 
growth was established in our laboratory (Nan Wang, PhD thesis 2014). In this model, 
subcutaneous injection of TS/A-SI-CLP stably expressing recombinant SI-CLP and control 
TS/A-EV (empty vector) cells was used and tumor growth was monitored for 21 day. SI-CLP 
was produced only as recombinant protein by TS/A-SI-CLP cells in this model, while no 
endogenous proteins was produced by TS/A cells, TAM or other cell types in tumor 
microenvironment enabling analysis of the effects of ectopically expressed SI-CLP. 
Preliminary data about the inhibitory role of SI-CLP in mouse model for breast carcinoma 
were obtained by Dr. Nan Wang (Nan Wang, PhD thesis 2014). It was demonstrated that SI-
CLP suppressed tumor growth of TS/A-derived tumors subcutaneously injected in BALB/c 
mice. This effect correlated with significantly reduced amount of stabilin-1+ TAM. Stabilin-1 
is known to directly interact with SI-CLP and to transport the biosynthetic SI-CLP to the 
lysosomal secretory pathway in alternatively activated macrophages
6
. Stabilin-1 is abundantly 
expressed on TAM both in human breast cancer and in murine models for breast 
adenocarcinoma
68,145
. Using stabilin-1 ko mice it was demonstrated that stabilin-1 has a tumor 
promoting effect in murine breast adenocarcinoma and melanoma models
68,129
. It was 
hypothesized that SI-CLP released from TS/A cells might change phenotype of stabilin-
1+TAM or reduce the infiltration of tumor-promoting stabilin-1+ TAM resulting in inhibited 
tumor growth. To address this hypothesis, the effect of SI-CLP in the TS/A-model was 
compared in wild type and stabilin-1 ko mice.  
Significant inhibition of tumor growth induced by TS/A-SI-CLP cells was observed in 
both BALB/c wt and stabilin-1 ko mice at all analyzed time points. The inhibition of SI-CLP 
on tumor growth was even more pronounced in stabilin-1 ko mice compared to wt mice. On 
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day 21 after tumor cells injection, the difference in tumor weight between TS/A-EV and 
TS/A-SI-CLP tumors in wt mice reached 1.47 times, while it reached 2.4 times in ko mice. 
These results suggest that SI-CLP mediated suppression of tumor growth does not require 
expression of stabilin-1 on TAM. Moreover, the data suggest that SI-CLP expression in the 
tumor tissue in combination with the absence of stabilin-1 on TAM have a synergistic 
suppressive effect on tumor growth. Stabilin-1 was shown to be intracellular sorting receptor 
for endogenously produced SI-CLP in macrophages
6
. However, it can be also hypothesized 
that stabilin-1 expressed on TAM can act as an endocytic receptor for the SI-CLP produced 
by TS/A-SI-CLP cells that results in deprivation of extracellular SI-CLP. This hypothesis can 
explain the increased tumor-suppressive effect of SI-CLP in the stabilin-1 ko mice compared 
with wt mice.  
YKL-40 was shown to stimulate proliferation of cancer cells lines HEK-293 and U-373 
MG cells
41
, and increased proliferation induced by YKL-40 was suggested to contribute to the 
tumor growth in the animal model for colorectal cancer
39
. However, the major mechanisms 
that promoted tumor growth in this model included recruitment of macrophages and 
angiogenesis. In our model system expression of the recombinant SI-CLP in TS/A cells has 
slight stimulatory effects on the TS/A cell proliferation in vitro (around 25% of increase), 
while SI-CLP has a strong suppressive effect on the tumor growth in vivo. Comparison of the 
migration ability of TS/A-EV and TS/A-SI-CLP cells in vitro also demonstrated that SI-CLP-
mediated suppression of tumor growth cannot be explained by its effect on tumor cell 
migration. Thus, it was concluded that changes in proliferation and migration of TS/A-SI-
CLP cells are not associated with reduced tumor growth in vivo, and prompted us to further 
investigate the effect of SI-CLP on the composition of tumor microenvironment.  
4.2 Effect of SI-CLP on angiogenesis. 
The major mechanism of YKL-40-mediated support of tumor growth was assigned to its 
pro-angiogenic activities
9,39,56
. Over-expression of YKL-40 in HCT-116 and MDA-MB-231 
cells promoted angiogenesis (evaluated by the levels of CD31+ expression) in mouse models 
for breast adenocarcinoma and colorectal carcinoma, while knockdown of the YKL-40 gene 
in U-87 MG cells decreased angiogenesis in vitro and in vivo
9
. In human breast cancer tissue, 
the intensity of YKL-40 staining was found to positively correlate with angiogenesis
9
. 
Moreover, YKL-40 was found to enhance the adhesion and migration of VSMC that 
supported angiogenesis
38
. All this data suggested that, similarly to YKL-40, SI-CLP can be 
involved in the regulation of angiogenesis. However, the analysis of CD31 expression in 
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TS/A-EV and TS/A-SI-CLP tumors using quantitative immunohistochemistry did not detect 
significant difference in tumor vascularization. Therefore, the suppressive effect of SI-CLP on 
tumor growth in the TS/A tumor model was not related to the reduced angiogenesis. 
Therefore, next question raised was whether SI-CLP has an effect on the amount and content 
of immune cells in tumor microenvironment, where TAM play a key role in the support of 
primary tumor growth. 
4.3 Effect of SI-CLP on TAM infiltration and phenotype. 
Since attenuated growth of TS/A-SI-CLP tumors was not attributed to changes in 
intrinsic properties of tumor cells (proliferation and migration) and angiogenesis, it was 
hypothesized that the possible mechanism of tumor growth inhibition might involve changes 
in intratumoral immunity (specifically, alterations in immune cell composition of the tumor 
microenvironment). The infiltration of immune cells in TS/A-EV and TS/A-SI-CLP tumor 
tissue was investigated using quantitative immunohistochemistry for the specific immune cell 
markers. CD68 was used as a general marker of TAM in TS/A tumor tissue and CD68 
positivity reflected the abundance of TAM in the tumor mass
68
. CD68 positivity was found to 
be significantly decreased in TS/A-SI-CLP tumors suggesting that SI-CLP has an inhibiting 
effect on TAM infiltration. The promoting effects of TAM in the progression of breast cancer 
are well-documented
85,93,146
, and reduced numbers of TAM in the tumor tissue are associated 
with delayed tumor progression
82
. Higher numbers of TAM in human breast cancer tissue 
predict a worse prognosis
97
. Other markers expressed on TAM include CD206 and stabilin-1. 
CD206 was identified as a prototype marker for alternative macrophage activation
147
. CD206 
is considered as a specific marker of tumor-supporting macrophages, and selective depletion 
of CD206 positive TAM in TS/A-derived tumors inhibits tumor growth and metastasis
132
. 
Stabilin-1 is a multifunctional clearance/sorting receptor expressed by alternatively activated 
macrophages
148
. We and others have recently demonstrated that stabilin-1 positive TAM 
facilitate tumor growth and metastasis in murine breast adenocarcinoma and melanoma 
models
68,129
. Decreased levels of CD206 and stabilin-1 expression in TS/A-SI-CLP tumors 
suggested that SI-CLP can inhibit intratumoral accumulation of TAM with tumor supporting 
activities that result in the delayed tumor growth. This assumption was supported by the fact 
that the fold change in CD206 and stabilin-1 expression was comparable to the fold change of 
CD68.  LYVE-1 is a frequently used as classical marker of lymphatic endothelium, however 
it can also be expressed by TAM subsets in murine model of TS/A mammary adenocarcinoma 
(Alexandru Gudima, Master thesis, 2012) and B16F1 melanoma
133
. LYVE-1 is frequently co-
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expressed with CD68 and stabilin-1 in TS/A tumor, while part of LYVE-1 can be also found 
on vessel-like structures that do no express macrophages markers (Alexandru Gudima, Master 
thesis, 2012). Reduction of LYVE-1 expression identified by quantitative 
immunohistochemical analysis in the TS/A-SI-CLP tumors was more pronounced compared 
with the reduction of CD206 and stabilin-1 expression, that can be explained by the additional 
suppressive effects of SI-CLP on lymphangiogenesis. In stabilin-1 ko mice, the effect of SI-
CLP on reducing the amount of CD68+, CD206+ and LYVE-1+ cells was comparable to wt 
mice, indicating that similarly to the effect on tumor growth, effect of SI-CLP on TAM 
content does not depend on stabilin-1 expression on TAM. 
The results of immunohistochemical analysis on TS/A-EV and TS/A-SI-CLP tumors 
suggest that SI-CLP influences the infiltration of macrophages to TAM-SI-CLP tumors. The 
chemotactic effects of chitinase-like proteins on immune cells have been already reported 
previously for YM-1 and YKL-40
37,39
. YM1 was shown to  induce the chemotaxis of bone 
marrow cells, eosinophils and T cells, but not macrophages derived from peritoneal exudate
37
. 
YKL-40 was shown to enhance the chemotaxis of human monocyte-like THP-1 cells
39
. Since 
SI-CLP shares similarity with YM1 and YKL-40, it was reasonable to assess whether SI-CLP 
has an effect on macrophage chemotaxis. In vitro experiment in a Transwell system 
demonstrated that purified SI-CLP protein as a chemotactic agent added to the lower chamber 
did not induce the chemotaxis of murine BMDM and human monocytes (data not shown). 
However, pre-incubation of BMDM with commercial purified SI-CLP or conditioned SI-
CLP-containing supernatant of BHK-21 cells infected with SI-CLP producing alphavirus 
resulted in the significant reduction of BMDM migration induced by CCL2. The specificity of 
this effect was additionally confirmed by the depletion of SI-CLP from BHK-21 supernatants 
using immunoprecipitation. Inhibition of CCL2-induced migration was also demonstrated for 
human freshly purified CD14+ monocytes pre-incubated with commercial purified human SI-
CLP. Thus, in contrast to the promoting effects of YM1 and YKL-40 in macrophage 
migration, SI-CLP demonstrated an inhibiting effect, that corresponds to the decreased 
amount of TAM in infiltrating TS/A-SI-CLP tumor compared to TS/A-EV tumors. Despite 
substantial similarity between SI-CLP, YKL-40 and YM1, SI-CLP clearly inhibited 
chemotaxis of macrophages whereas YKL-40 and YM1 facilitated chemotaxis of 
macrophages. This functional difference between closely related proteins suggest that 
macrophage infiltration in tumors can be coordinately regulated by chitinase-like protein 
networks. The mechanism of SI-CLP mediated inhibition of macrophage chemotaxis is 
currently unknown. It can be hypothesized that binding of SI-CLP with primary macrophages 
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may decrease the availability of CCR2 receptor on the cell surface of macrophages, which 
interferes the CCL2-CCR2 interaction. The binding of CCL2 with CCR2 is mediated by 
glycosaminoglycan, and formation of CCL2 tetramers induced by heparin is important for 
binding with glycosaminoglycan
149
. Like YKL-40, SI-CLP possesses strong affinity to 
heparin, and might interfere with tetramer formation of CCL2 through competitive binding 
with heparin.  
The results of quantitative histology on tumor sections as well as the results of 
chemotactic tests in vitro provided strong arguments that SI-CLP inhibits macrophage influx 
in the tumor mass. However, it was necessary to examine whether SI-CLP has an additional 
effect on the phenotype of infiltrating TAM since the expression of macrophage activation 
markers including CD206 and stabilin-1 differed between TS/A-EV and TS/A-SI-CLP tumors. 
In order to examine whether SI-CLP expression affects the TAM phenotype, TAM were 
isolated from TS/A-EV and TS/A-SI-CLP tumors and expression of surface markers and 
cytokines was analyzed by RT-PCR. However, the gene expression of CD206, LYVE-1 and 
stabilin-1 was not significantly changed between TAM isolated from TS/A-EV and TS/A-SI-
CLP tumors, indicating that the decrease of tumor supporting TAM (CD206+, stabilin-1+ 
TAM) results from the reduction of the amount of TAM in TS/A-SI-CLP tumors, but not by 
the direct effect of SI-CLP on TAM activation. The expression of other markers of 
macrophage polarization, including CD163, IL-1β, IL-6, TNF-α, and TGF-β, was also similar 
in TS/A-EV and TS/A-SI-CLP derived TAM.  Thus, the analysis did not reveal any 
significant effect of the presence of SI-CLP in the tumor microenvironment on macrophage 
phenotype. The data suggested that the expression of SI-CLP in TS/A tumor model does not 
affect these genes related to the type of TAM polarization.  
TAM are known to support the local tumor growth by enhancing the secretion of 
cytokines and growth factors that promote the proliferation of tumor cells
97,98
. In order to test 
whether TAM isolated from TS/A-SI-CLP have reduced tumor-promoting effect compared to 
TAM isolated from TS/A-EV tumors, TAM conditioned medium was used to stimulate TS/A 
cells. Conditioned medium of TAM strongly supported the proliferation of TS/A cells, but the 
supportive activity did not vary between TAM isolated from TS/A-EV and TS/A-SI-CLP 
tumors. Therefore, the major effect of SI-CLP that explained the suppression of tumor growth 
was the inhibition of infiltration of TAM with tumor-promoting phenotype.  
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4.4 Effect of SI-CLP on other immune cell recruitment. 
TAM are key cells of tumor microenvironment that also affect infiltration and phenotype 
of other innate and adaptive immune cells. Moreover, chitinase-like protein YM1 has a direct 
chemotactic effect on eosinophils and T cells
37
. Therefore, we investigated how the presence 
of SI-CLP in tumor mass can influence the content and amount of various types of immune 
cells in the tumor microenvironment. The amount of T cells in TS/A-EV and TS/A-SI-CLP 
tumors was investigated by quantitative immunohistological analysis of CD3, and less CD3+ 
cells were found in the TS/A-SI-CLP tumors in both BALB/c wt and stabilin-1 ko mice. 
CD8+ cytotoxic T cells play a crucial role in tumor rejection, while FoxP3+ regulatory T cells 
(Tregs) support tumor tolerance. Minor amount of CD8+ cells was found in the TS/A-EV and 
TS/A-SI-CLP tumors, and the presence of SI-CLP did not have statistically significant effect 
on the amount of CD8+ cells neither in wt nor in the stabilin-1 ko mice. However, 
significantly less CD4+ and FoxP3+ positive cells were found in TS/A-SI-CLP tumors. The 
effect of SI-CLP on the reduction of FoxP3+ cells did not depend on the expression of 
stabilin-1 on TAM and was similar in wt and stabilin-1 ko mice.  
Since the amount of T cells was reduced in the TS/A-SI-CLP tumors, it was 
hypothesized that the infiltration of T cells can be inhibited by SI-CLP protein, similar to its 
effect on macrophages. The effect of SI-CLP on the chemotaxis of T cells was studied in vitro 
using naïve T cells isolated from spleen of BALB/c mice. However, purified mouse SI-CLP 
did not show an inhibitory effect on T-cell migration towards CCL19 (positive control for 
chemotaxis of T cells) suggesting that reduced infiltration of T cells in the tumor tissue is due 
to reduced number of TAM in TS/A-SI-CLP tumor tissue. In addition, SI-CLP-mediated 
reduction of TAM can also explain reduced amount of FoxP3+ cells in the TS/A-SI-CLP 
tumors. Further analysis of other types of immune cells that regulate tumor growth 
demonstrated that the infiltration of eosinophils and neutrophils was not significantly changed 
between TS/A-EV and TS/A-SI-CLP tumors.  
In summary, the present study demonstrated that SI-CLP has a pronounced suppressive 
effect on the growth of breast adenocarcinoma, where SI-CLP inhibits recruitment of TAM 
with tumor-promoting phenotype. The inhibitory effect of SI-CLP on recruiting pro-tumor 
TAM has to be further examined in the experimental models for different types of cancer, for 
example colorectal cancer and glioblastoma, where TAM play a crucial role in the tumor 
progression. In perspective, tumor-suppressive properties of SI-CLP can be considered for the 
design of novel therapeutic approaches to target tumor-supportive TAM. 
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5 Summary 
SI-CLP belongs to the family of chitinase-like proteins that combine properties of 
cytokines and growth factors. SI-CLP was identified as an intracellular ligand for the 
multifunctional receptor stabilin-1, expressed on tumor-associated macrophages (TAM). 
YKL-40, a homologue of SI-CLP, has tumor-promoting activities in animal models for 
glioblastoma, colorectal carcinoma and breast adenocarcinoma, and elevated levels of YKL-
40 in human serum correlate with poor prognosis in various types of cancer. In contrast, 
previous data obtained in our laboratory demonstrated that SI-CLP has an inhibitory effect on 
tumor growth in mouse model for breast adenocarcinoma correlating with decreased amount 
of stabilin-1+TAM. However, the mechanisms of SI-CLP-mediated suppression of tumor 
growth remain to be unknown. The aims of the present study were to identify the functional 
role and possible mechanism of SI-CLP effects in cancer development using mouse model for 
breast adenocarcinoma. The effects of SI-CLP on the biology of cancer cells, tumor 
angiogenesis, and phenotype and amounts of immune cells in tumor microenvironment were 
analyzed. To examine whether expression of stabilin-1 on TAM is critical for the tumor-
suppressive effect of SI-CLP, TS/A cells stably transfected with SI-CLP (TS/A-SI-CLP) and 
with the control empty vector (control TS/A-EV) were injected subcutaneously into BALB/c 
wt and stabilin-1 knockout (ko) mice. The suppressive effects of SI-CLP on tumor growth in 
the stabilin-1 ko mice were similar to wt mice at all time points analyzed (from day 7 until 
day 21), indicating that SI-CLP does not require stabilin-1 expression on TAM for its 
intratumoral effects. In vitro analysis of TS/A-SI-CLP and TS/A-EV demonstrated that SI-
CLP does not suppress TS/A cell proliferation or migration. Quantitative 
immunohistochemistry demonstrated that the presence of SI-CLP does not affect tumor 
angiogenesis and infiltration of neutrophils and eosinophils in vivo. However, SI-CLP 
significantly inhibited infiltration of TAM in tumor mass without changing their tumor-
supporting phenotype. The direct inhibitory effect of SI-CLP on the CCL2 induced 
recruitment of mouse bone-marrow derived macrophages and human monocytes was 
demonstrated in vitro. Reduced amount of TAM in TS/A tumor tissue correlated with the 
decreased amount of FoxP3+ cells, while SI-CLP had no direct effect on T-cell migration in 
vitro. In summary, the results of the study demonstrated that SI-CLP suppresses growth on 
breast adenocarcinoma primarily by inhibiting the infiltration of tumor-associated 
macrophages and reducing tumor-supportive activities of tumor microenvironment.  
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